بیماری آلزایمر - ویکی‌پدیا، دانشنامهٔ آزاد
بیماری آلزایمر
از ویکی‌پدیا، دانشنامهٔ آزاد
پرش به:					 ناوبری ، 					 جستجو
فارسی
English
برای فیلمی با این نام،
آلزایمر (فیلم)
را ببینید.
این مقاله نیازمند
ویکی‌سازی
است. لطفاً با توجه به
راهنمای ویرایش
و
شیوه‌نامه ، محتوای آن را بهبود بخشید.
بیماری آلزایمر
Comparison of a normal aged brain (left) and the brain of a person with Alzheimer's (right). Differential characteristics are pointed out.
آی‌سی‌دی - ۱۰
G 30 ,
F 00
آی‌سی‌دی - ۹
331.0 ,
290.1
اُمیم
۱۰۴۳۰۰
دادگان بیماری‌ها
۴۹۰
مدلاین پلاس
000760
ای‌مدیسین
neuro/۱۳
پیشنت پلاس
بیماری آلزایمر
سمپ
D000544
مرور ژن
[۱]
بیماری آلزایمر
(به
انگلیسی :
Alzheimer's disease ) که به اختصار آلزایمر خوانده می‌شود، یک نوع اختلال عملکرد مغزی است که بتدریج توانایی‌های ذهنی بیمار تحلیل می‌رود. بارزترین تظاهر
زوال عقل
اختلال حافظه‌است. اختلال حافظه معمولاً بتدریج ایجاد شده و پیشرفت می‌کند. در ابتدا اختلال حافظه به وقایع و آموخته‌های اخیر محدود می‌شود ولی بتدریج خاطرات قدیمی هم آسیب می‌بینند. بیمار پاسخ سئوالی را که چند لحظه قبل پرسیده‌است فراموش می‌کند و مجدداً همان سؤال را می‌پرسد. بیمار وسایلش را گم می‌کند و نمی‌داند کجا گذاشته‌است. در خرید و پرداخت پول دچار مشکل می‌شود و نمی‌تواند حساب دارائیش را نگه دارد. بتدریج در شناخت دوستان و آشنایان و نام بردن اسامی آنها نیز مشکل ایجاد می‌شود. کم‌کم مشکل مسیر یابی پیدا شده و اگر تنها از منزل بیرون برود ممکن است گم شود. در موارد شدیدتر حتی در تشخیص
اتاق خواب ، آشپزخانه، دستشویی و حمام در منزل خودش هم مشکل پیدا می‌کند. بروز اختلال در حافظه و روند تفکر سبب آسیب عملکردهای اجتماعی و شخصی بیمار شده و در نتیجه ممکن است سبب افسردگی، عصبانیت و پرخاشگری بیمار شود.
یکی از مشکلات زوال عقل بروز توهم و هذیان است. مثلاً بیمار فکر کند همسرش به وی خیانت کرده‌است و یا همسایگان و پرستارش قصد آسیب رساندن و توطئه علیه وی را دارند. بیمار ممکن است به فرزندانش بدبین شود. گاهی اوقات بیمار افرادی را مثلا والدین فوت شده یا اقوام را که نیستند و حضور ندارند میبینند.
در موارد شدید بیمار برای انجام کارهای اولیه شخصی نیاز به کمک پیدا می‌کند و ممکن است توانایی کنترل ادرار و مدفوع را هم از دست دهد. بیمار دچار زوال عقل ممکن است در تکلم و یافتن کلمات مناسب مشکل پیدا کند و در نتیجه کم حرف و گوشه گیر شود. در موارد پیشرفته تر بیمار آگاهیش را نسبت به بیماری از دست داده و نمی‌داند دچار ناتوانی در انجام برخی کارها است و ممکن است کارهای خطر ساز انجام دهد. بتدریج ممکن است توانایی حرکتی بیمار هم دستخوش آسیب شده و مکرراً تعادلش را از دست داده زمین بخورد.
آلزایمر رایج‌ترین شکل زوال عقل است. علائم این بیماری با از دست دادن قدرت حفظ اطلاعات بخصوص حافظهٔ موقت در دوران پیری آغاز شده و به‌تدریج با از دست دادن قدرت تشخیص زمان،
افسردگی ، از دست دادن قدرت تکلم، گوشه‌گیری و سرانجام مرگ در اثر ناراحتی‌های تنفسی به پایان می‌رسد. مرگ پس از پنج تا ده سال از بروز علائم اتفاق می‌افتد؛ اما بیماری حدود بیست سال قبل از ظهور علائم آغاز شده‌است. این بیماری با از دست رفتن
سیناپسهای
نورونها
در برخی مناطق
مغز ، نکروزه [۱]
شدن سلول‌های مغز در مناطق مختلف سیستم عصبی، ایجاد ساختارهای پروتئینی کروی شکلی به نام پلاک‌های پیری (SP) در خارج نورون‌های برخی مناطق مغز و ساختارهای پروتئینی رشته‌های به نام NFT در جسم سلولی نورون‌ها، مشخص می‌شود.
این بیماری علاج‌ناپذیر را اولین بار روانپزشک آلمانی به نام
آلویز آلزایمر [۲]
در سال ۱۹۰۶ میلادی معرفی کرد. غالباً این بیماری در افراد بالای ۶۵سال بروز می‌یابد؛ گر چه آلزایمر زودرس (با شیوع کمتر) ممکن است زودتر از این سن رخ دهد. در سال ۲۰۰۶ میلادی ۲۶٫۶ میلیون نفر در جهان به این بیماری مبتلا بودند و پیش‌بینی می‌شود که در سال ۲۰۵۰ میلادی از هر ۸۵ نفر یک مبتلا به آلزایمر وجود داشته باشد.
روز جهانی آلزایمر : همه ساله روز ۲۱ سپتامبر یا ۳۰ شهریور به مناسبت
روز جهانی آلزایمر
در دنیا مراسم و همایش‌های مختلف برگزار می‌شود. شعار سال ۲۰۰۸ این روز ( No time to lose ) است، به این معنی که زمانی برای تلف کردن نداریم.
پنج درصد جمعیت ۶۵ ساله و بالاتر به بیماری آلزایمر متوسط تا شدید مبتلا هستند و این در حالیست که ۱۰ تا ۱۵ درصد سالمندان در همین
گروه سنی
از بیماری آلزایمر خفیف رنج می‌برند. [۳]
محتویات
۱
تاریخچه
۲
پروتئنهای آمیلوئیدی
۳
درمان بیماری آلزایمر
۳.۱
درمان‌ های غیر دارویی
۳.۲
درمان های دارویی
۴
بهترین و موثرترین و مهم ترین روش ها و راه ها برای درمان آلزایمر
۵
آلزایمر و تغذیه
۶
آلزایمر و گروه‌های خونی
۷
پیشگیری
۷.۱
راه‌های تشخیص
۸
منابع
۹
پیوند به بیرون
۱۰
توضیحات
تاریخچه [ ویرایش ]
آگوست دتر
در سال ۱۹۰۱،
روان‌شناس
و
عصب‌شناس
آلمانی « آلویز آلزایمر » اولین مورد این بیماری را کشف و در مورد آن نوشت، که بعدها به بیماری آلزایمر معروف شد. بیمار یک زن ۵۰ ساله بود به اسم «آگوست دتر». آلویز آلزایمر این زن را از زمان بستری شدنش در آسایشگاهی در شهر فرانکفورت تا زمان مرگ او در سال ۱۹۰۶ همراهی کرد، [۴] [۵]
پروتئنهای آمیلوئیدی [ ویرایش ]
در بیماری آلزایمر ساختارهای
پروتئینی
کروی شکلی در خارج نورون‌های برخی مناطق مغز و ساختارهای پروتئینی رشته‌ای در جسم سلولی نورون‌ها، تشکیل می‌شود. این ساختارهای پروتئینی که به آنها اجسام آمیلوئیدی گفته می‌شود، در اثر برخی تغییرات در
پروتئوم
سلول‌های عصبی
وبهم خوردن تعادل و تغییر در میزان و یا ساختار پروتئین‌های پرسینیلین، آپولیپوپروتئینE، سینوکلئین، و پپتید آمیلوئیدبتا ایجاد می‌شود. یکی از مهم‌ترین پروتئین‌هایی که در ایجاد آلزایمر نقش دارد، پروتئین پیش‌ساز آمیلوئید (APP) نام دارد. این پروتئین در سلول‌های
دستگاه عصبی
بیان می‌شود و در اتصال سلول‌ها به هم، تماس سلول‌ها و اتصال به
ماتریکس خارج سلولی
و اسکلت سلولی نقش دارد. پروتئین APP به‌وسیلهٔ سه نوع آنزیم پروتئولیتیک پردازش می‌شود. آنزیم‌های آلفا، بتا و گاما- سکرتاز، به ترتیب پروتئین APP را در
اسیدهای آمینه
۶۷۸، ۶۷۱ و ۷۱۱برش می‌دهند. با اثر آنزیم‌های گاما و بتا سکرتازبلا بر پروتئین APP، به ترتیب، پپتیدهایی به نام آمیلوئیدبتا۴۰ (دارای ۴۰ اسید آمینه) وآمیلوئیدبتا۴۲ (دارای ۴۲ اسیدآمینه) ایجاد می‌شوند. در حالت عادی مقدار این قطعات در سلول‌ها کم است و به‌سرعت تجزیه می‌شود؛ اما اگر در پروتئوم سلول‌های عصبی این تعادل برهم بخورد و مقدار این قطعات افزایش یابد، ساختارهای پروتئینی کروی و درنتیجه آلزایمر ایجاد می‌شود. در بیماران مبتلا به
سندروم داون
(تریزومی ۲۱) میزان بیان پروتئین APP افزایش می‌یابد و علائمی شبیه آلزایمر مشاهده می‌شود که ممکن است به علت افزایش مقدار پپتید آمیلوئید بتا۴۲ باشد؛ زیرا ژن پروتئین APP بر روی
کروموزوم
۲۱ قرار دارد.
درمان بیماری آلزایمر [ ویرایش ]
در حال حاضر درمان بیماری آلزایمر بیشتر شامل درمان‌های علامتی، درمان اختلالات رفتاری و داروهای کاهنده سیر پیشرفت بیماری است.
درمان‌ های غیر دارویی [ ویرایش ]
از راه‌های غیر دارویی کاستن از پرخاشگری و بیقراری، شناسایی و رفع عللی است که سبب پرخاشگری بیمار می‌شود. مثلاً از تغییر محیط زندگی و جابجا کردن وسایل وی باید اجتناب کرد. گاهی اوقات حضور افراد بیگانه و ناآشنا سبب ترس و بی قراری وی می‌شود. ماساژ بیمار و معطر کردن محیط و موزیک آرام در برخی بیماران سبب کاهش بیقراری می‌شود. ورزش‌های سبک و کارهای ساده مثل
قدم زدن
یا حتی کندن
علف‌های هرز
باغچه می‌تواند سبب آرامش بیمار شود.
درمان های دارویی [ ویرایش ]
گرچه هنوز درمانی برای بیماری آلزایمر وجود ندارد اما با استفاده از داروها می‌توان سیر پیشرفت بیماری را کم کرد و از شدت اختلال حافظه و مشکلات رفتاری بیمار کاست. داروهای مورد تایید برای بیماری آلزایمر شامل موارد زیر است.
داروهای آرامبخش و ضد جنون : اگر با روش‌های غیر دارویی نتوان رفتارهای آزاردهنده، بی قراری و پرخاشگری بیمار را کمتر کرد می‌توان از داروهای جدید ضد جنون مثل اولانزاپین، کوتیاپین و ریسپریدون استفاده کرد. گاهی اوقات افسردگی سبب پرخاشگری بیمار است که با استفاده از
داروهای ضد افسردگی
مثل فلوکستین می‌توان آن را درمان کرد.
داروهای ضد کولین استراز : در بیماری آلزایمر مقدار
استیل کولین
که یکی از واسطه‌هایی شیمیایی مداخله گر در حافظه‌است کم می‌شود. داروهای مختلفی برای افزایش مقدار استیل کولین پایانه‌های عصبی استفاده می‌شوند از جمله ریواستیگمین (Exelon)، دانپزیل (Aricept)، و گالانتامین (Razadyne). این داروها سبب بهبود حافظه، عملکرد شناختی و عملکرد اجتماعی بیمار می‌شوند. این داروها تا حدودی رفتارهای غیر طبیعی بیمار را نیز اصلاح می‌کنند. مشکل عمده این داروها عوارض گوارشی، تهوع، استفراغ، دل پیچه و اسهال است که با افزایش تدریجی دارو، مصرف همراه صبحانه و شام و با مایعات یا
آب میوه
از شدت عوارض کاسته می‌شود.
ممانتین(Ebixa, Namenda) : داروی دیگری که در درمان موارد متوسط تا شدید بیماری آلزایمر استفاده می‌شود و تا حدودی هم اثرات محافظتی بر روی سلولهای مغزی دارد ممانتین است. این دارو نیز سبب بهتر شدن توانایی شناختی و حافظه بیمار می‌شود. گیجی و منگی مهمترین عوارض این دارو هستند. دارو را می‌توان همراه با غذا مصرف کرد. داروهایی که اثر بخشی آنها به تایید نرسیده‌است: داروها مختلف شیمیایی و گیاهی وجود دارند که بر اساس برخی مطالعات برای بیماری آلزایمر توصیه شده‌اند اما اثر بخشی آنها هنوز به تایید نرسیده‌است. ویتامین‌ها مثل ویتامینE،
ویتامین‌های گروه ب ، امگا ۳، استروژن، جینکوبیلوبا، داروهای ضد التهاب مثل بروفن از این دسته داروها هستند.
رژیم غذایی
سالم شامل مصرف روزانه سبزی و میوه و کاهش مصرف
چربی‌های اشباع
به علاوه مصرف مناسب
مواد غذایی
حاوی ویتامین‌های «آ، سی و ای» یکی از راه‌های مهم پیشگیری از آلزایمر است. [۶]
گاما سکرتاز سابقاً" برای درمان
آلزایمر
مورد آزمایش قرار گرفته بود. [۷]
اخیرا محققان آمریکایی با بررسی نتایج یک پژوهش دریافته اند که داروهای فشار خون که برای درمان بیماران مبتلا به فشار خون بالا استفاده می شود ، خطر بروز آلزایمر را در افراد کاهش می دهد. این احتمال وجود دارد که فشار خون بالا اثر حفاظتی داشته باشد و یا ممکن است چیزی که افراد مبتلا به فشار خون بالا اغلب در معرض آن قرار می گیرند مانند داروهای فشار خون از آنها در برابر ابتلا به آلزایمر محافظت می کند. [۸]
بهترین و موثرترین و مهم ترین روش ها و راه ها برای درمان آلزایمر [ ویرایش ]
معطر کردن محیط خواب و خانه
باغبانی
آرامش داشتن و کاهش پرخاشگری و بی قراری
ماساژ دادن
کاهش دیابت
شرکت در فعالیت های اجتماعی
خوابیدن به اندازه کافی
کم کردن کلسترول بد خون
عرق ریختن و ورزش کردن ( شنا و راه رفتن : حداقل 3 ساعت در روز )
مطالعه و کم کردن افسردگی
با مهربانی و لطافت با او صحبت کردن
کاهش چاقی
کاهش فشار خون
حفظ شعر و حل جدول
شعر خواندن و آواز خواندن
حفظ و خواندن شعر های جدید و غیر تکراری
گوش کردن به موسیقی آرام و ملایم
هر راهی که به کاهش سکته های قلبی و مغزی کمک می کمند ، به کاهش آلزایمر نیز کمک می کند .
استفاده کم تر از نمک و جایگزین کردن آن با ادویه ها خصوصا زردچوبه و دارچین
خوردن آب کافی
پروتین خون
گوشت سالم و استفاده از دامی که علف طبیعی خورده باشد
کاهش گوشت قرمز و استفاده متنوع از انواع گوشت ها
کاهش قند خون
خوردن کاکایو تلخ
خوردن قهوه به مقدار کافی
خوردن مواد آنتی اکسیدان دار مثل مرکبات و مواد دارای ویتامین سی C
خوردن کدوی سیز ، کلم بروکلی و گوجه فرنگی بو طور مداوم
خوردن غذا های دریایی
خوردن ماهیان خاویاری ، ماهی غزل آلا و غزل آلای رنگین کام ، اره ماهی ، ماهی خامخالی ، شاه ماهی و ساردین
خوردن میوه های خشک شده مخصوصا آلو ، انجیر و خرما
خوردن ماهی و امگا 3 از طریق دانه ها و ماهی ها
خوردن پروتین های بدون چربی
خوردن غذا های حاوی آب بالا مثل میوه های آب دار ، سوپ و شیر
خوردن امگا 3 و گوشت گوساله (گوشت گوساله 3 برابر گوشت معمولی امگا 3 دارد )
استفاده از روغن های گیاهی مثل کلرا ، روغن دانه کتان و روغن گردو
خوردن انگور قرمز
خوردن میوه های قرمز رنگ و تیره
خوردن لوبیا ( 3 بار در هفته )
خوردن آجیل و مغز ها و دانه ها ( 5 بار در هفته ) (گردو ، مویز ، بادام هندی و پسته)
خوردن اجیل باعث کم کردن کلسترول بد می شود
خوردن غلات سبوس دار و دانه ها
خوردن زغال اخته
خوردن انواع توت (فرنگی ، شاه توت)
خوردن ماهی سالمون
استفاده از طیور در برنامه غذایی
خوردن سالاد با غذا و حدقال یک سبزی
استفاده از گیاه ریواس
استفاده از بوی معطر اکالیپتوس
اسید فولویک و ویتامین ب آلزایمر را کاهش می دهند و این عناصر در آسپرین یافت می شوند .
از ظروف آلومینیومی استفاده نکنید .
مراقب مقدار عناصر آهن و مس در خون خود باشید .
مرتبا آزمایش خون بدهید و اگر برایتان ممکن است خون اهدا کنید .
آلزایمر و تغذیه [ ویرایش ]
پژوهشگران دانشگاه پزشکی شیکاگو با بررسی عادت غذایی ۶۰۰۰ نفر دریافتند که آن دسته از افرادی که دچار مشکلات فراموشی و نظایر آن نیستند، در عادت غذایی خود غذاهای سرشار از
ویتامین ای
گنجانده‌اند. ویتامین ای،
رادیکال‌های آزاد
را که محتملاً می‌توانند به سلول‌های مغز آسیب بزنند، مهار می‌کند. [۹] [۱۰]
آلزایمر و گروه‌های خونی [ ویرایش ]
گروه خونی
افراد می‌تواند در ابتلای آن‌ها به بیماری‌های زوال شناختی مانند آلزایمر تاثیرگذار باشد. گروه خونی نقش مهمی در رشد
سیستم ایمنی بدن
ایفا کرده و ممکن است باعث خطر بالاتر ابتلا به زوال شناختی شود. افراد دارای گروه خونی O از
ماده خاکستری
بیشتری در
مغز
خود نسبت به گروههای خونی A ،B و AB برخوردارند که این امر به حفاظت در برابر بیماری‌هایی مانند آلزایمر کمک خواهد کرد. دارندگان گروه خونی O از ماده خاکستری بیشتری در بخش خلفی
مخچه
برخوردارند. در مقایسه، افراد با گروههای خونی A، B یا AB دارای حجم کوچکتری از ماده خاکستری در مناطق
تمپورال
و
لیمبیک
مغز
از جمله
هیپوکامپ
چپ هستند که یکی از نخستین بخشهایی از مغز است که در اثر آلزایمر، آسیب می‌بیند. [۱۱]
پیشگیری [ ویرایش ]
هنوز راه ثابت شده‌ای برای جلوگیری از ابتلاء به آلزایمر وجودندارد، چراکه عامل و یا عوامل اصلی این بیماری ناشناخته است. [۱۲]
پژوهش ها نشان می دهند که دیابت و هر بیماری دیگری که بر قند خون تاثیر داشته باشد، در عملکرد مغز و سیستم اعصاب اختلال وارد می کند.افزایش قند خون، سبب افزایش سطح آمولویید بتا در بدن بیمار می شود. آمولویید بتا نشان دهنده پپتیدهایی از اسید آمینه هستند که مهمترین جزء پلاک های آمیولویید در مغز بیماران مبتلا به آلزایمر به شمار می آیند. [۱۳]
با اینحال یکی از بهترین راههایی که امروزه برای پیشگیری از ابتلاء به آلزایمر بیان می‌شود، همان راههایی است که برای کاهش خطر ابتلاء به بیماری‌های قلبی بیان می‌شوند. [۱۲]
کنترل موارد مهمی که بر سلامت
قلب
تأثیر دارد، مانند، فشارخون بالا، چاقی و
دیابت
ممکن‌است بتواند به پیشگیری از ابتلاء به آلزایمر کمک کند. [۱۲]
افزایش تحرک و فعالیت جسمی،
روابط اجتماعی
و رژیم غذایی سالم می‌تواند، خطر ابتلاء به آلزایمر را کاهش دهد. [۱۲]
برای پیشگیری، استفاده از ذهن مثل یادگیری دو زبان و حل جدول، معاشرت با دیگران، انتخاب زندگی سالم، کنترل کلسترول، جلوگیری از چاقی، تغذیه سالم، مصرف
امگا ۳
و ماهی، ورزش کردن و توجه به فشار و قند و پیشگیری از ضربه سر کمک کننده است.
راه‌های تشخیص [ ویرایش ]
چنانچه شخص ۴ یا ۵ نشانه زیر را داشته باشد، باید به پزشک مراجعه کند. [۱۴]
اختلال حافظه که فعالیتهای روزانه را دچار آشکار می‌کند.
مشکلات در انجام کارهای عادی مثلاً فراموش می‌کند، غذا بپزد
ضعف بیان و استفاده از کلمات نامناسب برای صحبت کردن
گم کردن زمان مکان مثلاً روز و شب
کاهش قضاوت (اختلال در تصمیم‌گیری)
اختلال تفکر ذهنی (حسابهای مالی – ارقام)
جا به جا کردن اجسام مثلاً ساعت را روی گاز می‌گذارد
تغییرات در حالت و رفتار (خنده – گریه – عصبانیت)
انگیزه را از دست می‌دهند و بی توجه می‌شوند
تغییر شخصیت (منزوی شدن – عصبانی شدن)
اخیرا محققان کالج لندن در انگلستان موفق به شناسایی پروتئینی در خون شده اند که عامل توسعه اختلال شناختی است و بسیار قبل تر از مشاهده علایم آلزایمر، می تواند بیماری را پیش بینی کند. نتایج این پژوهش که روی بیش از یکهزار پروتئین خونی در 212 داوطلب صورت گرفته است، نشان می دهد که پروتئین MAPKAPK5 در خون افرادی که به آلزایمر مبتلا می شوند، کمتر از افراد عادی است. [۱۵]
یکی دیگر از روش های جدید تشخیص زودهنگام آلزایمر از طریق بزاق است. با بررسی سطح هورمون استرس در بزاق می توان احتمال آلزایمر و زوال عقل در سالمندان را تشخیص داد. [۱۶]
منابع [ ویرایش ]
بیو ایران - سایت مرجع بیوشیمی به
زبان فارسی
www.bioiran.net
Contributeurs à Wikipédia, "Maladie d'Alzheimer," Wikipédia, l'encyclopédie libre,
http://fr.wikipedia.org/w/index.php?title=Maladie_d'Alzheimer&oldid=27089184
(Page consultée le mars 7, 2008).
آلزایمر در فرانسه-fr
ارگانیزاسیون آلزایمر-en
پایگاه آموزشی بیماریهای مغز و اعصاب
آلزایمر در فرانسه-Ir
پیوند به بیرون [ ویرایش ]
برای آشنایی بیشتر و بسیار بهتر با این بیماری
انجمن آلزایمر ایران
توضیحات [ ویرایش ]
↑
necrose: فاسدشدن
↑
Alois Alzheimer
↑
پنج درصد جمعیت ۶۵ ساله و بالاتر به بیماری آلزایمر متوسط تا شدید مبتلا هستند
↑
Alzheimer: Uber eine eigenartige Erkrankung der Hirnrinde.. In: Allg. Z. Psychiat. Psych. -Gerichtl. Med.. 64, Nr. 1-2, 1907, S. 146–148
↑
Konrad Maurer, Ulrike Maurer: Alzheimer: the life of a physician and the career of a disease. New York: Columbia University Press 2003,
ISBN 0-231-11896-1
↑
بیماری آلزایمر و روش‌های تشخیص و کنترل آن - مازیار مهدوی فر - رادیو زمانه
↑
cell.com
↑
داروی فشار خون عامل کاهش خطر ابتلا به آلزایمر
. [خبرگزاری جمهوری اسلامی
http://www.irna.ir ]
↑
The Best Brain Food You Should Be Eating
مجله
Reader's Digest
↑
ALZHEIMER뭩 PREVENTION
alzheimersinfo.org
↑
خبرگزاری انتخاب
کدام گروه‌های خونی در معرض ابتلا به آلزایمر هستند؟
به نقل از خبرنامه تحقیقات مغز
↑
۱۲٫۰
۱۲٫۱
۱۲٫۲
۱۲٫۳
«خلاصه‌ای بر بیماری آلزایمر» . راستینه.
↑
احتمال ابتلا به آلزایمر در دیابتی ها بیشتر است
. [خبرگزاری جمهوری اسلامی(ایرنا)
http://www.irna.ir ]
↑
ساده‌ترین راه‌های تشخیص "آلزایمر"
خبرگزاری انتخاب
↑
تشخیص آلزایمر با آزمایش خون
. [خبرگزاری جمهوری اسلامی
http://www.irna.ir ]
↑
پیش بینی زوال شناختی سالمندان با بررسی بزاق
. [خبرگزاری جمهوری اسلامی(ایرنا)
http://www.irna.ir ]
در
ویکی‌انبار
پرونده‌هایی دربارهٔ
بیماری آلزایمر
موجود است.
ن
ب
و
اختلالات روانی ،
هیجانی و رفتاری
عصبی/علامتی
دمانس
اختلال خفیف شناختی
بیماری آلزایمر
دمانس مولتی انفارکت
بیماری پیک
بیماری کروتزفلد جاکوب
بیماری هانتینگتون
بیماری پارکینسون
مجموعه دمانس ایدز
دمانس فرونتوتمپورال
سان‌داونینگ (دمانس)
سرگردانی (دمانس)
طیف اوتیسمی
اوتیسم
نشانگان آسپرگر
سندرم ساوانت
درخودماندگی ذکرنشه
اوتیسم با عملکرد بالا
متفرقه
روان‌آشفتگی
نشانگان پس از ضربه مغزی
نشانگان مغز ارگانیک
مواد
روان‌فعال ,
سوء مصرف مواد , سوء مصرف دارو و اختلالات وابسته به مواد
مسمومیت / مصرف بیش از حد
وابستگی فیزیکی
وابستگی به مواد
اثر ریباند
ریباند دوگانه
ترک
روان‌گسیختگی ، اختلال شخصیت اسکیزوتایپی
و
هذیانی
جنون
اختلال اسکیزوافکتیو
اختلال اسکیزوفرنیفرم
جنون واکنشی گذرا
اسکیزوفرنی
اسکیزوفرنی آشفته
اختلال هذیان
فولی ا دو
اختلال خلقی
شیدایی
اختلال دوقطبی
( دوقطبی ۱
دوقطبی ۲
سایکلوتایمیا
دوقطبی ذکرنشده )
افسردگی
( اختلال افسردگی اساسی
دیستایمیا
اختلال خلقی فصلی
افسردگی آتیپیک
غم و اندوه پس از ارگاسم
افسردگی مالیخولیایی )
روان‌نژندی , ناشی از
استرس
و
اختلالات سوماتوفرم
اختلال اضطراب
هراس
هراس از مکان‌های باز
اختلال اضطراب اجتماعی
اضطراب اجتماعی
( مردم گریزی )
هراس‌های ویژه
( تنگناهراسی )
هراس خاص اجتماعی
سایر
اختلال وحشت
وحشت‌زدگی
اختلال اضطراب فراگیر
اختلال وسواسی جبری
استرس
( تنش کاربردی
اختلال تنش‌زای پس از رویداد )
اختلالات سازگاری
اختلالات سازگاری
اختلال سوماتوفرم
اختلال روان‌تنی
اختلال بدشکلی بدنی
خودبیمارانگاری
بیمارستان هراسی
نشانگان داکوستا
درد روانی
اختلال تبدیلی
( نشانگان گانسر
گلوبوس فارنژیس )
نوراستنیا
بیماری روان‌زاد بزرگ
اختلالات گسستگی
اختلال تجزیه هویت
فراموشی روانی
گریز گسسته
اختلال دی پرسونالیزیشن
فیزیولوژیک / فیزیکی-رفتاری
اختلال خوردن
بی‌اشتهایی عصبی
پرخوری روانی
اختلال نشخوار
سندرم‌های خوردن ذکر نشده
غیرارگانیک
اختلالات خواب
( پرخوابی
بی‌خوابی )
پاراسومنیا
( اختلال رفتاری حرکات سریع چشم
هراس شبانه
کابوس )
اختلالات جنسی
میل جنسی
( دلزدگی جنسی
اعتیاد به رابطه جنسی )
برانگیختگی جنسی
( اختلال برانگیختگی جنسی مونث )
اختلال نعوظ
ارگاسم
( عدم ارگاسم
تاخیر در انزال
انزال زودرس
فقدان لذت جنسی )
درد
( انقباض غیرارادی مهبل
دیسپارونیا )
پس از زایمان
افسردگی پس‌زایمانی
جنون پس‌زایمانی
شخصیت و رفتار بالغین
هویت جنسیتی
و
آشفتگی جنسیتی
اختلال بلوغ جنسی
جهت‌یابی جنسی اگودیستونیک
اختلال رابطه جنسی
انحراف جنسی
( تماشاگری جنسی
فتیش جنسی )
سایر
اختلال شخصیت
اختلال کنترل تکانه
( جنون دزدی
اختلال موکنی
جنون آتش‌افروزی )
رفتار تکرارشونده بدن محور
اختلال ساختگی
( نشانگان مونشهاوزن )
اختلال‌های روانی تشخیص داده شده در کودکی
عقب‌ماندگی ذهنی
عقب‌ماندگی ذهنی وابسته به ایکس
( نشانگان لوجان فرینز )
رشد روانی
( اختلال‌های رشد )
اختلال‌های تحولی خاص
اختلال‌های تحولی فراگیر
رفتاری و هیجانی
اختلال کم‌توجهی - بیش‌فعالی
اختلال رفتار
( اختلال نافرمانی-تحریک )
اختلال هیجانی
( اختلال اضطرابی جدایی )
عملکرد اجتماعی
( سکوت انتخابی
اختلال دلبستگی واکنشی
اختلال دلبستگی مهارنشده )
اختلال تیک
( نشانگان ژیل دولاتوره )
اختلال گفتاری
( لکنت زبان
ناهنجاری زبانی )
اختلال حرکت
( کلیشه‌ای )
علائم و طبقه‌بندی نشده‌ها
روان‌گسیختگی کاتاتونی
حاملگی اشتباه
اختلال انفجاری گهگاهی
بی‌قراری روانی
اعتیاد جنسی
کلیشگی
تشنج‌های غیر-صرعی روانی
نشانگان کلوور-بوسی
ن
ب
و
داروشناسی :
سیستم طبقه‌بندی آناتومیکی درمانی شیمیایی
دستگاه گوارش /
دگرگشت
( ای‌تی‌سی )
کنترل اسید معده
پاداسیدها
H 2
آنتاگونیست
مهارکننده‌های پروتون پمپ
داروهای ضد تهوع
ملین
داروهای ضد اسهال
داروهای ضد چاقی
داروهای ضد دیابت
ویتامین
نمک‌های معدنی
خون
و اندام‌های
خونساز
داروهای ضد ترومبوز
داروهای ضد پلاکت
ضد انعقاد
داروهای ترومبولیت
داروهای ضد خون‌ریزی
پلاکت
انعقاد خون
آنتی فیبرینولیتیک
دستگاه گردش خون
داروهای قلبی/ داروهای ضد آنژین
گلیکوزیدهای قلبی
داروهای ضد آریتمی
داروهای محرک قلب
داروهای کاهنده فشار خون
داروهای ادرارآور
داروهای گشادکننده عروق
بلوک‌کننده گیرنده آدرنرژیک بتا
بلوک‌کننده کانال کلسیم
سامانه رنین-آنژیوتانسین
بازدارنده‌های آنزیم مبدل آنژیوتانسین
آنتاگونیست آنژیوتانسین ۲
بازدارنده رنین
داروهای کاهنده چربی خون
استاتین
فیبرات
Bile acid sequestrant
پوست
مرطوب‌کننده
جوش دهنده زخم
داروهای ضد خارش
ضد پسوریازیس
پانسمان پیشرفته
دستگاه ادراری تناسلی
Hormonal contraception
Fertility agents
سِرم
هرمون‌های جنسی
دستگاه درون‌ریز
Hypothalamic-pituitary hormone
کورتیکواستروئید
گلوکوکورتیکوئید
مینرالوکورتیکوئید
هورمون جنسی
هورمون تیروئیدو عوامل آنتی تیروئید
عفونت‌ها
و
آلودگی‌ها
آنتی‌میکروب‌ها :
آنتی‌بیوتیکها
( ضد قارچها )
داروهای ضد قارچ
داروهای ضد ویروس
پادانگل
Antiprotozoals
ضدانگلها
Ectoparasiticide s
ایمنوگلوبولین
واکسن
بیماریهای
بدخیمی
شیمی‌درمانی
Antimetabolite s
عوامل آلکیله کننده
Spindle poison s
شیمی‌درمانی
مهارکننده‌های توپوایزومراز
بیماری‌های
دستگاه ایمنی
ایمونوتراپیها
Immunostimulant s
Immunosuppressants
ماهیچه‌ها ،
استخوانها
و
مفصل‌ها
Anabolic steroid s
ضد التهاب
داروهای ضد التهاب غیر استروئیدی
Antirheumatics
کورتیکواستروئید
شل‌کننده‌های عضلات
بیس فسفونات
مغز
و
اعصاب
مُسکن یا دردزُدا
داروهای بی‌هوشی
General
Local
Anorectic s
اختلال کم‌توجهی - بیش‌فعالی
Antiaddictive s
Anticonvulsant s
بیماری آلزایمر
داروهای ضد افسردگی
Antimigraine Agent s
Antiparkinson's Agent s
داروهای ضدروان‌پریشی
داروهای ضداضطراب
Depressant s
Entactogen s
Entheogen s
نشئگی s
Hallucinogens
Psychedelic s
Dissociative s
Deliriant s
خواب‌آورها / آرام‌بخش
داروهای تثبیت‌کننده خلق
Neuroprotective s
Nootropic s
Neurotoxin s
Orexigenic s
Serenic s
داروهای محرک
Wakefulness-Promoting Agent s
دستگاه تنفس
ضد احتقان
Bronchodilator s
Cough medicine s
H 1
antagonist s
دستگاه حسی
چشم‌پزشکی
گوش‌شناسی
سایر
طبقه‌بندی‌ها
پادزهرها
Contrast media
رادیوفارماکولوژی
پانسمان
ن
ب
و
آسیب‌شناسی
در
دستگاه عصبی ٬
دستگاه عصبی مرکزی
التهاب
مغز
آنسفالیت
آنسفالیت ویروسی
Herpesviral encephalitis
Limbic encephalitis
Encephalitis lethargica
Cavernous sinus thrombosis
دمل مغزی
Amoebic
طناب نخاعی
Myelitis :
فلج اطفال
Demyelinating disease
Transverse myelitis
Tropical spastic paraparesis
Epidural abscess
هردو
Encephalomyelitis
Acute disseminated
مننگوانسفالیت
مغز /
انسفالوپاتی
دجنراتیو
دستگاه خارج هرمی
و
اختلالات حرکتی
Basal ganglia disease
پارکینسونیزم
پارکینسون
Postencephalitic
نشانگان نورولپتیک بدخیم
PKAN
Tauopathy
PSP
Striatonigral degeneration
Hemiballismus
بیماری هانتینگتون
OA
دیسکینزی
دیستونی
Status dystonicus
Spasmodic torticollis
Meige's
بلفارواسپاسم
حرکت‌پریشی
رقصاک
Choreoathetosis
Myoclonus
Myoclonic epilepsy
بی‌قراری حرکتی
رعشه
Essential tremor
Intention tremor
سندروم پای بی‌قرار
Stiff person
زوال عقل
Tauopathy
بیماری آلزایمر
Early-onset
Primary progressive aphasia
Frontotemporal dementia / Frontotemporal lobar degeneration
Pick's
Dementia with Lewy bodies
Posterior cortical atrophy
Vascular dementia
نقائص میتوکندریایی
Leigh's disease
Demyelinating
autoimmune
فلج چندگانه
سندرم دویک
Schilder's disease
hereditary
آدرنولکودیستروفی
Alexander
کاناوان
کرابه
ام.ال
PMD
VWM
MFC
CAMFAK syndrome
Central pontine myelinolysis
Marchiafava-Bignami disease
Alpers' disease
Episodic/
paroxysmal
Seizure / صرع
Focal
Generalised
بحران صرعی
Myoclonic epilepsy
سردرد
میگرن
Familial hemiplegic
سردرد خوشه‌ای
Tension
Cerebrovascular
حمله ایسکمی گذرا
Amaurosis fugax
Transient global amnesia
زبان‌پریشی
سکته مغزی
MCA
ACA
PCA
Foville's
Millard-Gubler
Lateral medullary
Weber's
Lacunar stroke
اختلال خواب
بی‌خوابی
Hypersomnia
وقفه تنفسی در خواب
Obstructive
Ondine's curse
حمله خواب
کاتاپلکسی
نشانگان کلاین-لوین
Circadian rhythm sleep disorder
Advanced sleep phase disorder
Delayed sleep phase disorder
Non-24-hour sleep–wake disorder
پرواززدگی
مایع مغزی-نخاعی
فشار داخل جمجمه‌ای
هیدروسفالی / NPH
Choroid plexus papilloma
Idiopathic intracranial hypertension
ادم مغزی
Intracranial hypotension
دیگر
فتق مغزی
سندروم رایز
انسفالوپاتی کبدی
Toxic encephalopathy
Hashimoto's encephalopathy
طناب نخاعی /
میلوپاتی
نخاع‌گشادگی
Syringobulbia
Morvan's syndrome
Vascular myelopathy
Foix-Alajouanine syndrome
Spinal cord compression
هر دو مورد
Degenerative
SA
آتاکسی فردریش
Ataxia telangiectasia
بیماری‌های نورون حرکتی
نورون حرکتی فوقانی
فقط:
Primary lateral sclerosis
Pseudobulbar palsy
Hereditary spastic paraplegia
نورون حرکتی تحتانی
فقط:
Distal hereditary motor neuropathies
Spinal muscular atrophies
SMA
SMAX1
SMAX2
DSMA1
Congenital DSMA
SMA-PCH
SMA-LED
SMA-PME
Progressive muscular atrophy
Progressive bulbar palsy
Fazio–Londe
Infantile progressive bulbar palsy
هردو:
اسکلروز جانبی آمیوتروفیک
"Alzheimer" redirects here. For other uses, see
Alzheimer (disambiguation) .
Alzheimer's disease
Comparison of a normal aged brain (left) and the brain of a person with Alzheimer's (right). Characteristics that separate the two are pointed out.
Classification and external resources
Specialty
Neurology
ICD - 10
G30 ,
F00
ICD - 9-CM
331.0 ,
290.1
OMIM
104300
DiseasesDB
490
MedlinePlus
000760
eMedicine
neuro/13
Patient UK
Alzheimer's disease
MeSH
D000544
GeneReviews
NBK1161
Alzheimer's disease
( AD ), also known as
Alzheimer disease , or just
Alzheimer's , accounts for 60% to 70% of cases of
dementia . [ 1 ] [ 2 ]
It is a chronic
neurodegenerative
disease that usually starts slowly and gets worse over time. [ 1 ] [ 2 ]
The most common early symptom is difficulty in remembering recent events ( short-term memory
loss). [ 1 ]
As the disease advances, symptoms can include
problems with language ,
disorientation
(including easily getting lost),
mood swings , loss of
motivation , not managing
self care , and
behavioural issues . [ 1 ] [ 2 ]
As a person's condition declines, they often withdraw from family and society. [ 1 ]
Gradually, bodily functions are lost, ultimately leading to death. [ 3 ]
Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years. [ 4 ] [ 5 ]
The cause of Alzheimer's disease is poorly understood. [ 1 ]
About 70% of the risk is believed to be
genetic
with many
genes
usually involved. [ 6 ]
Other risk factors include a history of
head injuries ,
depression , or
hypertension . [ 1 ]
The disease process is associated with
plaques
and
tangles
in the
brain . [ 6 ]
A probable diagnosis is based on the history of the illness and
cognitive testing
with
medical imaging
and
blood tests
to rule out other possible causes. [ 7 ]
Initial symptoms are often mistaken for normal ageing. [ 1 ]
Examination of brain tissue is needed for a definite diagnosis. [ 6 ]
Mental
and
physical exercise , and avoiding
obesity
may decrease the risk of AD. [ 6 ]
There are no medications or supplements that decrease risk. [ 8 ]
No treatments stop or reverse its progression, though some may temporarily improve symptoms. [ 2 ]
Affected people increasingly rely on others for assistance, often placing a burden on the
caregiver ; the pressures can include social, psychological, physical, and economic elements. [ 9 ]
Exercise programs are beneficial with respect to
activities of daily living
and can potentially improve outcomes. [ 10 ]
Treatment of behavioral problems or
psychosis
due to dementia with
antipsychotics
is common but not usually recommended due to there often being little benefit and an increased risk of early death. [ 11 ] [ 12 ]
In 2010, there were between 21 and 35 million people worldwide with AD. [ 2 ] [ 4 ]
It most often begins in people over 65 years of age, although 4% to 5% of cases are
early-onset Alzheimer's
which begin before this. [ 13 ]
It affects about 6% of people 65 years and older. [ 1 ]
In 2010, dementia resulted in about 486,000 deaths. [ 14 ]
It was first described by, and later named after, German psychiatrist and pathologist
Alois Alzheimer
in 1906. [ 15 ]
In
developed countries , AD is one of the most financially costly diseases. [ 16 ] [ 17 ]
Contents
1
Characteristics
1.1
Pre-dementia
1.2
Early
1.3
Moderate
1.4
Advanced
2
Cause
2.1
Genetics
2.2
Cholinergic hypothesis
2.3
Amyloid hypothesis
2.4
Tau hypothesis
2.5
Other hypotheses
3
Pathophysiology
3.1
Neuropathology
3.2
Biochemistry
3.3
Disease mechanism
4
Diagnosis
4.1
Criteria
4.2
Techniques
4.3
Early diagnosis
5
Prevention
5.1
Medication
5.2
Lifestyle
5.3
Diet
6
Management
6.1
Medications
6.2
Psychosocial intervention
6.3
Caregiving
6.4
Feeding tubes
7
Prognosis
8
Epidemiology
9
History
10
Society and culture
10.1
Social costs
10.2
Caregiving burden
10.3
Notable cases
11
Research directions
11.1
Imaging
12
References
13
Further reading
14
External links
Characteristics
Stages of Alzheimer's disease [ 18 ]
Effects of ageing on memory
but not AD
Forgetting
things occasionally
Misplacing items sometimes
Minor
short-term memory
loss
Not remembering exact details
Early stage Alzheimer's
Not remembering episodes of forgetfulness
Forgets names of family or friends
Changes may only be noticed by close friends or relatives
Some confusion in situations outside the familiar
Middle stage Alzheimer's
Greater difficulty remembering recently learned information
Deepening confusion in many circumstances
Problems with sleep
Trouble knowing where they are
Late stage Alzheimer's
Poor ability to think
Problems speaking
Repeats same conversations
More abusive, anxious, or paranoid
The disease course is divided into four stages, with a progressive pattern of
cognitive
and
functional
impairment .
Pre-dementia
The first symptoms are often mistakenly attributed to
ageing
or
stress . [ 19 ]
Detailed
neuropsychological testing
can reveal mild cognitive difficulties up to eight years before a person fulfills the clinical criteria for
diagnosis
of AD. [ 20 ]
These early symptoms can affect the most complex
daily living activities . [ 21 ]
The most noticeable deficit is
short term memory
loss, which shows up as difficulty in remembering recently learned facts and inability to acquire new information. [ 20 ] [ 22 ]
Subtle problems with the
executive functions
of
attentiveness ,
planning , flexibility, and
abstract thinking , or impairments in
semantic memory
(memory of meanings, and concept relationships) can also be symptomatic of the early stages of AD. [ 20 ]
Apathy
can be observed at this stage, and remains the most persistent
neuropsychiatric
symptom throughout the course of the disease. [ 23 ]
Depressive symptoms, irritability and reduced awareness of subtle memory difficulties are also common. [ 24 ]
The preclinical stage of the disease has also been termed
mild cognitive impairment
(MCI). [ 22 ]
This is often found to be a transitional stage between normal ageing and
dementia . MCI can present with a variety of symptoms, and when memory loss is the predominant symptom, it is termed "amnestic MCI" and is frequently seen as a
prodromal
stage of Alzheimer's disease. [ 25 ]
Early
In people with AD, the increasing impairment of learning and memory eventually leads to a definitive diagnosis. In a small percentage, difficulties with language, executive functions,
perception
( agnosia ), or execution of movements ( apraxia ) are more prominent than memory problems. [ 26 ]
AD does not affect all memory capacities equally.
Older memories
of the person's life ( episodic memory ), facts learned ( semantic memory ), and
implicit memory
(the memory of the body on how to do things, such as using a fork to eat) are affected to a lesser degree than new facts or memories. [ 27 ] [ 28 ]
Language problems
are mainly characterised by a shrinking
vocabulary
and decreased word
fluency , leading to a general impoverishment of oral and
written language . [ 26 ] [ 29 ]
In this stage, the person with Alzheimer's is usually capable of communicating basic ideas adequately. [ 26 ] [ 29 ] [ 30 ]
While performing
fine motor tasks
such as writing, drawing or dressing, certain movement coordination and planning difficulties (apraxia) may be present, but they are commonly unnoticed. [ 26 ]
As the disease progresses, people with AD can often continue to perform many tasks independently, but may need assistance or supervision with the most cognitively demanding activities. [ 26 ]
Moderate
Progressive deterioration eventually hinders independence, with subjects being unable to perform most common activities of daily living. [ 26 ]
Speech difficulties become evident due to an inability to
recall vocabulary , which leads to frequent incorrect word substitutions ( paraphasias ). Reading and writing skills are also progressively lost. [ 26 ] [ 30 ]
Complex motor sequences become less coordinated as time passes and AD progresses, so the risk of falling increases. [ 26 ]
During this phase, memory problems worsen, and the person may fail to recognise close relatives. [ 26 ]
Long-term memory , which was previously intact, becomes impaired. [ 26 ]
Behavioural and
neuropsychiatric
changes become more prevalent. Common manifestations are
wandering ,
irritability
and
labile affect , leading to crying, outbursts of unpremeditated
aggression , or resistance to caregiving. [ 26 ]
Sundowning
can also appear. [ 31 ]
Approximately 30% of people with AD develop
illusionary misidentifications
and other
delusional
symptoms. [ 26 ]
Subjects also lose insight of their disease process and limitations ( anosognosia ). [ 26 ]
Urinary incontinence
can develop. [ 26 ]
These symptoms create
stress
for relatives and carers, which can be reduced by moving the person from
home care
to other
long-term care facilities . [ 26 ] [ 32 ]
Advanced
During the final stages, the patient is completely dependent upon caregivers. [ 26 ]
Language is reduced to simple phrases or even single words, eventually leading to complete loss of speech. [ 26 ] [ 30 ]
Despite the loss of verbal language abilities, people can often understand and return emotional signals. Although aggressiveness can still be present, extreme
apathy
and
exhaustion
are much more common symptoms. People with Alzheimer's disease will ultimately not be able to perform even the simplest tasks independently;
muscle mass
and mobility deteriorate to the point where they are bedridden and unable to feed themselves. The cause of death is usually an external factor, such as infection of
pressure ulcers
or
pneumonia , not the disease itself. [ 26 ]
Cause
The cause for most Alzheimer's cases is still mostly unknown except for 1% to 5% of cases where genetic differences have been identified. [ 33 ]
Several competing
hypotheses
exist trying to explain the cause of the disease:
Genetics
The genetic heritability of Alzheimer's disease (and memory components thereof), based on reviews of twin and family studies, range from 49% to 79%. [ 34 ] [ 35 ]
Around 0.1% of the cases are familial forms of
autosomal
(not
sex-linked )
dominant
inheritance, which have an onset before age 65. [ 36 ]
This form of the disease is known as
early onset familial Alzheimer's disease . Most of autosomal dominant familial AD can be attributed to mutations in one of three genes: those encoding
amyloid precursor protein
(APP) and
presenilins
1 and 2. [ 37 ]
Most mutations in the APP and presenilin genes increase the production of a small protein called
A β 42, which is the main component of
senile plaques . [ 38 ]
Some of the mutations merely alter the ratio between Aβ42 and the other major forms—e.g., Aβ40—without increasing Aβ42 levels. [ 39 ] [ 40 ]
This suggests that presenilin mutations can cause disease even if they lower the total amount of A β
produced and may point to other roles of presenilin or a role for alterations in the function of APP and/or its fragments other than A β . There exist variants of the APP gene which are protective. [ 41 ]
Most cases of Alzheimer's disease do not exhibit autosomal-dominant inheritance and are termed sporadic AD, in which environmental and genetic differences may act as
risk factors . The best known genetic risk factor is the inheritance of the ε4
allele
of the
apolipoprotein E
(APOE). [ 42 ] [ 43 ]
Between 40 and 80% of people with AD possess at least one APOEε4 allele. [ 43 ]
The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes. [ 36 ]
Like many human diseases, environmental effects and genetic modifiers result in incomplete
penetrance . For example, certain Nigerian populations do not show the relationship between dose of APOEε4 and incidence or age-of-onset for Alzheimer's disease seen in other human populations. [ 44 ] [ 45 ]
Early attempts to screen up to 400 candidate genes for association with late-onset sporadic AD (LOAD) resulted in a low yield. [ 36 ] [ 37 ]
More recent
genome-wide association studies
(GWAS) have found 19 areas in genes that appear to affect the risk. [ 46 ]
These genes include:
CASS4 ,
CELF1 ,
FERMT2 ,
HLA-DRB5 ,
INPP5D ,
MEF2C ,
NME8 ,
PTK2B ,
SORL1 ,
ZCWPW1 ,
SlC24A4 ,
CLU ,
PICALM ,
CR1 ,
BIN1 ,
MS4A ,
ABCA7 ,
EPHA1 , and
CD2AP . [ 46 ]
Mutations in the
TREM2
gene have been associated with a 3 to 5 times higher risk of developing Alzheimer's disease. [ 47 ] [ 48 ]
A suggested mechanism of action is that when TREM2 is mutated, white blood cells in the brain are no longer able to control the amount of beta amyloid present.
Cholinergic hypothesis
The oldest, on which most currently available drug therapies are based, is the
cholinergic
hypothesis , [ 49 ]
which proposes that AD is caused by reduced synthesis of the
neurotransmitter
acetylcholine . The cholinergic hypothesis has not maintained widespread support, largely because medications intended to treat acetylcholine deficiency have not been very effective. Other cholinergic effects have also been proposed, for example, initiation of large-scale aggregation of amyloid, [ 50 ]
leading to generalised
neuroinflammation . [ 51 ]
Amyloid hypothesis
In 1991, the
amyloid
hypothesis
postulated that extracellular amyloid beta (A β ) deposits are the fundamental cause of the disease. [ 52 ] [ 53 ]
Support for this postulate comes from the location of the gene for the
amyloid precursor protein
(APP) on
chromosome 21 , together with the fact that people with
trisomy 21
( Down Syndrome ) who have an extra
gene copy
almost universally exhibit at least the earliest symptoms of AD by 40 years of age. [ 54 ] [ 55 ]
Also, a specific isoform of apolipoprotein,
APOE4 , is a major genetic risk factor for AD. Whilst apolipoproteins enhance the breakdown of beta amyloid, some isoforms are not very effective at this task (such as APOE4), leading to excess amyloid buildup in the brain. [ 56 ]
Further evidence comes from the finding that
transgenic
mice that express a mutant form of the human APP gene develop fibrillar amyloid plaques and Alzheimer's-like brain pathology with spatial learning deficits. [ 57 ]
An experimental vaccine was found to clear the amyloid plaques in early human trials, but it did not have any significant effect on dementia. [ 58 ]
Researchers have been led to suspect non-plaque A β
oligomers
(aggregates of many monomers) as the primary pathogenic form of A β . These toxic oligomers, also referred to as amyloid-derived diffusible ligands (ADDLs), bind to a surface receptor on neurons and change the structure of the synapse, thereby disrupting neuronal communication. [ 59 ]
One receptor for A β
oligomers may be the
prion protein , the same protein that has been linked to
mad cow disease
and the related human condition,
Creutzfeldt–Jakob disease , thus potentially linking the underlying mechanism of these
neurodegenerative
disorders with that of Alzheimer's disease. [ 60 ]
One study found possible evidence of human to human transmission. [ 61 ]
In 2009, this theory was updated, suggesting that a close relative of the beta-amyloid protein, and not necessarily the beta-amyloid itself, may be a major culprit in the disease. The theory holds that an amyloid-related mechanism that prunes neuronal connections in the brain in the fast-growth phase of early life may be triggered by ageing-related processes in later life to cause the neuronal withering of Alzheimer's disease. [ 62 ]
N-APP, a fragment of APP from the peptide's
N-terminus , is adjacent to beta-amyloid and is cleaved from APP by one of the same enzymes. N-APP triggers the self-destruct pathway by binding to a neuronal receptor called death receptor 6 (DR6, also known as
TNFRSF21 ). [ 62 ]
DR6 is highly expressed in the human brain regions most affected by Alzheimer's, so it is possible that the N-APP/DR6 pathway might be hijacked in the
ageing brain
to cause damage. In this model, beta-amyloid plays a complementary role, by depressing synaptic function.
Tau hypothesis
In Alzheimer's disease, changes in tau protein lead to the disintegration of microtubules in brain cells.
The
tau hypothesis
proposes that
tau protein
abnormalities initiate the disease cascade. [ 53 ]
In this model,
hyperphosphorylated
tau begins to pair with other threads of tau. Eventually, they form
neurofibrillary tangles
inside nerve cell bodies. [ 63 ]
When this occurs, the
microtubules
disintegrate, destroying the structure of the cell's
cytoskeleton
which collapses the neuron's transport system. [ 64 ]
This may result first in malfunctions in biochemical communication between neurons and later in the death of the cells. [ 65 ]
Other hypotheses
A neurovascular hypothesis has been proposed which state that poor functioning of the
blood brain barrier
may be involved. [ 66 ]
Herpes simplex
virus type 1 has been proposed to play a causative role in people carrying the susceptible versions of the
apoE
gene. [ 67 ]
The cellular
homeostasis
of ionic copper, iron, and zinc is disrupted in AD, though it remains unclear whether this is produced by or causes the changes in proteins. These ions affect
and
are affected by tau, APP, and APOE. [ 68 ]
Some studies have shown an increased risk of developing AD with
environmental factors
such as the intake of
metals , particularly
aluminium . [ 69 ]
The quality of some of these studies has been criticised, [ 70 ] [ 71 ]
and other studies have concluded that there is no relationship between these environmental factors and the development of AD. [ 72 ]
Some have hypothesised that dietary
copper
may play a causal role. [ 73 ]
While some studies suggest that
extremely low frequency
electromagnetic fields may increase the risk for Alzheimer's disease, [ 74 ]
reviewers found that further epidemiological and laboratory investigations of this hypothesis are needed. [ 75 ]
Smoking is a significant AD risk factor. [ 76 ]
Systemic markers
of the
innate immune system
are risk factors for late-onset AD. [ 77 ]
Another hypothesis asserts that the disease may be caused by age-related
myelin
breakdown in the brain. Iron released during myelin breakdown is hypothesised to cause further damage. Homeostatic myelin repair processes contribute to the development of proteinaceous deposits such as
beta-amyloid
and
tau . [ 78 ] [ 79 ] [ 80 ]
Oxidative stress
and dys- homeostasis
of
biometal
metabolism may be significant in the formation of the pathology. [ 81 ] [ 82 ] [ 83 ]
In this point of view, low molecular weight antioxidants such as
melatonin
would be promising. [ 84 ]
AD individuals show 70% loss of
locus coeruleus
cells that provide
norepinephrine
(in addition to its neurotransmitter role) that locally diffuses from "varicosities" as an endogenous
anti-inflammatory
agent in the microenvironment around the neurons,
glial cells , and blood vessels in the
neocortex
and
hippocampus . [ 85 ]
It has been shown that norepinephrine stimulates mouse microglia to suppress A β -induced production of cytokines and their
phagocytosis
of A β . [ 85 ]
This suggests that degeneration of the locus coeruleus might be responsible for increased A β
deposition in AD brains. [ 85 ]
There is tentative evidence that exposure to
air pollution
may be a contributing factor to the development of Alzheimer's disease. [ 86 ]
Pathophysiology
Main article:
Biochemistry of Alzheimer's disease
Histopathologic
image of senile plaques seen in the cerebral cortex of a person with Alzheimer's disease of presenile onset. Silver impregnation.
Neuropathology
Alzheimer's disease is characterised by loss of
neurons
and
synapses
in the
cerebral cortex
and certain subcortical regions. This loss results in gross
atrophy
of the affected regions, including degeneration in the
temporal lobe
and
parietal lobe , and parts of the
frontal cortex
and
cingulate gyrus . [ 51 ]
Degeneration is also present in brainstem nuclei like the
locus coeruleus . [ 87 ]
Studies using
MRI
and
PET
have documented reductions in the size of specific brain regions in people with AD as they progressed from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults. [ 88 ] [ 89 ]
Both
amyloid plaques
and
neurofibrillary tangles
are clearly visible by
microscopy
in brains of those afflicted by AD. [ 90 ]
Plaques are dense, mostly
insoluble
deposits of
beta-amyloid
peptide
and
cellular
material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of ageing, the brains of people with AD have a greater number of them in specific brain regions such as the temporal lobe. [ 91 ]
Lewy bodies
are not rare in the brains of people with AD. [ 92 ]
Biochemistry
Enzymes act on the APP (amyloid precursor protein) and cut it into fragments. The beta-amyloid fragment is crucial in the formation of senile plaques in AD.
Alzheimer's disease has been identified as a
protein misfolding
disease ( proteopathy ), caused by
plaque
accumulation of abnormally folded
amyloid beta
protein, and
tau
protein in the brain. [ 93 ]
Plaques are made up of small
peptides , 39–43  amino acids
in length, called
amyloid beta
(A β ). A β
is a fragment from the larger
amyloid precursor protein
(APP). APP is a
transmembrane protein
that penetrates through the neuron's membrane. APP is critical to neuron growth, survival, and post-injury repair. [ 94 ] [ 95 ]
In Alzheimer's disease, an unknown
enzyme
in a
proteolytic
process causes APP to be divided into smaller fragments. [ 96 ]
One of these fragments gives rise to fibrils of amyloid beta, which then form clumps that deposit outside neurons in dense formations known as
senile plaques . [ 90 ] [ 97 ]
AD is also considered a
tauopathy
due to abnormal aggregation of the
tau protein . Every neuron has a
cytoskeleton , an internal support structure partly made up of structures called
microtubules . These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the
axon
and back. A protein called
tau
stabilises the microtubules when
phosphorylated , and is therefore called a
microtubule-associated protein . In AD, tau undergoes chemical changes, becoming
hyperphosphorylated ; it then begins to pair with other threads, creating
neurofibrillary tangles
and disintegrating the neuron's transport system. [ 98 ]
Disease mechanism
Exactly how disturbances of production and aggregation of the beta-amyloid peptide give rise to the pathology of AD is not known. [ 99 ] [ 100 ]
The amyloid hypothesis traditionally points to the accumulation of beta-amyloid
peptides
as the central event triggering neuron degeneration. Accumulation of aggregated amyloid
fibrils , which are believed to be the toxic form of the protein responsible for disrupting the cell's
calcium
ion
homeostasis , induces
programmed cell death
( apoptosis ). [ 101 ]
It is also known that A β
selectively builds up in the
mitochondria
in the cells of Alzheimer's-affected brains, and it also inhibits certain
enzyme
functions and the utilisation of
glucose
by neurons. [ 102 ]
Various inflammatory processes and
cytokines
may also have a role in the pathology of Alzheimer's disease.
Inflammation
is a general marker of
tissue
damage in any disease, and may be either secondary to tissue damage in AD or a marker of an immunological response. [ 103 ]
There is increasing evidence of a strong interaction between the neurons and the immunological mechanisms in the brain. Obesity and systemic inflammation may interfere with immunological processes which promote disease progression. [ 104 ]
Alterations in the distribution of different
neurotrophic factors
and in the expression of their receptors such as the
brain-derived neurotrophic factor
(BDNF) have been described in AD. [ 105 ] [ 106 ]
Diagnosis
PET scan
of the brain of a person with AD showing a loss of function in the temporal lobe
Alzheimer's disease is usually diagnosed based on the person's
medical history , history from relatives, and behavioural observations. The presence of characteristic
neurological
and
neuropsychological
features and the
absence of alternative conditions
is supportive. [ 107 ] [ 108 ]
Advanced
medical imaging
with
computed tomography
(CT) or
magnetic resonance imaging
(MRI), and with
single-photon emission computed tomography
(SPECT) or
positron emission tomography
(PET) can be used to help exclude other cerebral pathology or subtypes of dementia. [ 109 ]
Moreover, it may predict conversion from
prodromal
stages (mild cognitive impairment) to Alzheimer's disease. [ 110 ]
Assessment of intellectual functioning
including memory testing can further characterise the state of the disease. [ 19 ]
Medical organisations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians. The diagnosis can be confirmed with very high accuracy
post-mortem
when brain material is available and can be examined
histologically . [ 111 ]
Criteria
The
National Institute of Neurological and Communicative Disorders and Stroke
(NINCDS) and the
Alzheimer's Disease and Related Disorders Association
(ADRDA, now known as the
Alzheimer's Association ) established the most commonly used
NINCDS-ADRDA Alzheimer's Criteria
for diagnosis in 1984, [ 111 ]
extensively updated in 2007. [ 112 ]
These criteria require that the presence of
cognitive impairment , and a suspected dementia syndrome, be confirmed by
neuropsychological testing
for a clinical diagnosis of possible or probable AD. A
histopathologic
confirmation including a
microscopic
examination of
brain tissue
is required for a definitive diagnosis. Good
statistical reliability
and
validity
have been shown between the diagnostic criteria and definitive histopathological confirmation. [ 113 ]
Eight cognitive domains are most commonly impaired in AD— memory ,
language ,
perceptual skills ,
attention , constructive abilities,
orientation ,
problem solving
and functional abilities. These domains are equivalent to the NINCDS-ADRDA Alzheimer's Criteria as listed in the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR) published by the
American Psychiatric Association . [ 114 ] [ 115 ]
Techniques
Neuropsychological
screening tests
can help in the diagnosis of AD. In the tests, people are instructed to copy drawings similar to the one shown in the picture, remember words, read, and subtract serial numbers.
Neuropsychological tests
such as the
mini–mental state examination
(MMSE) are widely used to evaluate the cognitive impairments needed for diagnosis. More comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease. [ 116 ] [ 117 ]
Neurological examination
in early AD will usually provide normal results, except for obvious cognitive impairment, which may not differ from that resulting from other diseases processes, including other causes of dementia.
Further neurological examinations are crucial in the
differential diagnosis
of AD and other diseases. [ 19 ]
Interviews with family members are also utilised in the assessment of the disease. Caregivers can supply important information on the daily living abilities, as well as on the decrease, over time, of the person's
mental function . [ 118 ]
A caregiver's viewpoint is particularly important, since a person with AD is commonly unaware of his own
deficits . [ 119 ]
Many times, families also have difficulties in the detection of initial dementia symptoms and may not communicate accurate information to a physician. [ 120 ]
Supplemental testing provides extra information on some features of the disease or is used to rule out other diagnoses.
Blood tests
can identify other causes for dementia than AD [ 19 ] —causes which may, in rare cases, be reversible. [ 121 ]
It is common to perform
thyroid function tests , assess
B12 , rule out
syphilis , rule out metabolic problems (including tests for kidney function, electrolyte levels and for diabetes), assess levels of heavy metals (e.g. lead, mercury) and anaemia. (It is also necessary to rule out
delirium ).
Psychological tests
for
depression
are employed, since depression can either be concurrent with AD (see
Depression of Alzheimer disease ), an early sign of cognitive impairment, [ 122 ]
or even the cause. [ 123 ] [ 124 ]
Early diagnosis
Emphasis in Alzheimer's research has been placed on diagnosing the condition before symptoms begin. [ 125 ]
A number of biochemical tests have been developed to allow for early detection. One such test involves the analysis of
cerebrospinal fluid
for beta-amyloid or tau proteins, [ 126 ]
both total tau protein and phosphorylated tau 181P
protein concentrations. [ 127 ] [ 128 ]
Searching for these proteins using a
spinal tap
can predict the onset of Alzheimer's with a
sensitivity
of between 94% and 100%. [ 127 ]
When used in conjunction with existing
neuroimaging
techniques, doctors can identify people with significant memory loss who are already developing the disease. [ 127 ]
Prevention
Intellectual activities such as playing
chess
or regular social interaction have been linked to a reduced risk of AD in epidemiological studies, although no causal relationship has been found.
At present, there is no definitive evidence to support that any particular measure is effective in preventing AD. [ 129 ]
Global studies of measures to prevent or delay the onset of AD have often produced inconsistent results. Epidemiological studies have proposed relationships between certain modifiable factors, such as diet, cardiovascular risk, pharmaceutical products, or intellectual activities among others, and a population's likelihood of developing AD. Only further research, including clinical trials, will reveal whether these factors can help to prevent AD. [ 130 ]
Medication
Although cardiovascular risk factors, such as
hypercholesterolaemia ,
hypertension ,
diabetes , and smoking, are associated with a higher risk of onset and course of AD, [ 131 ] [ 132 ]
statins , which are
cholesterol
lowering drugs, have not been effective in preventing or improving the course of the disease. [ 133 ] [ 134 ] [ 135 ]
Long-term usage of
non-steroidal anti-inflammatory drugs
(NSAIDs) is associated with a reduced likelihood of developing AD. [ 136 ]
Evidence also support the notion that NSAIDs can reduce inflammation related to amyloid plaques. [ 136 ]
No prevention trial has been completed. [ 136 ]
They do not appear to be useful as a treatment. [ 137 ]
Hormone replacement therapy , although previously used, may increase the risk of dementia. [ 138 ]
Lifestyle
People who engage in intellectual activities such as reading, playing board games, completing crossword puzzles, playing
musical instruments , or regular
social interaction
show a reduced risk for Alzheimer's disease. [ 139 ]
This is compatible with the
cognitive reserve
theory, which states that some life experiences result in more efficient neural functioning providing the individual a cognitive reserve that delays the onset of dementia manifestations. [ 139 ]
Education delays the onset of AD syndrome, but is not related to earlier death after diagnosis. [ 140 ]
Learning a second language even later in life seems to delay getting Alzheimer disease. [ 141 ]
Physical activity
is also associated with a reduced risk of AD. [ 140 ]
Diet
People who eat a
healthy ,
Japanese
or
Mediterranean diet
have a lower risk of AD, [ 142 ]
and a Mediterranean diet may improve outcomes in those with the disease. [ 143 ]
Those who eat a diet high in saturated fats and simple carbohydrates ( mono-
and
disaccharide ) have a higher risk. [ 144 ]
The mediterranean diet's beneficial cardiovascular effect has been proposed as the mechanism of action. [ 145 ]
Conclusions on dietary components have at times been difficult to ascertain as results have differed between population-based studies and randomised controlled trials. [ 142 ]
There is limited evidence that light to moderate use of alcohol, particularly red wine, is associated with lower risk of AD. [ 146 ]
There is tentative evidence that
caffeine
may be protective. [ 147 ]
A number of foods high in
flavonoids
such as
cocoa , red wine, and tea may decrease the risk of AD. [ 148 ] [ 149 ]
Reviews on the use of
vitamins
and minerals have not found enough consistent evidence to recommend them. This includes vitamin A, [ 150 ] [ 151 ]
C, [ 152 ] [ 153 ]
E, [ 153 ] [ 154 ]
selenium , [ 155 ]
zinc , [ 156 ]
and folic acid with or without vitamin B 12 . [ 157 ]
Additionally vitamin E is associated with health risks. [ 153 ]
Trials examining
folic acid
(B9) and other B vitamins failed to show any significant association with cognitive decline. [ 158 ]
In those already affected with AD adding
docosahexaenoic acid , an omega-3 fatty acid, to the diet has not been found to slow decline. [ 159 ]
Curcumin
as of 2010 has not shown benefit in people even though there is tentative evidence in animals. [ 160 ]
There is inconsistent and unconvincing evidence that
ginkgo
has any positive effect on cognitive impairment and dementia. [ 161 ]
As of 2008 there is no concrete evidence that
cannabinoids
are effective in improving the symptoms of AD or dementia. [ 162 ]
Some research in its early stages however looks promising. [ 163 ]
Management
There is no cure for Alzheimer's disease; available treatments offer relatively small symptomatic benefit but remain
palliative
in nature. Current treatments can be divided into pharmaceutical, psychosocial and caregiving.
Medications
Three-dimensional
molecular model
of
donepezil , an
acetylcholinesterase inhibitor
used in the treatment of AD symptoms
Molecular structure of
memantine , a medication approved for advanced AD symptoms
Five medications are currently used to treat the cognitive problems of AD: four are
acetylcholinesterase inhibitors
( tacrine ,
rivastigmine ,
galantamine
and
donepezil ) and the other ( memantine ) is an
NMDA receptor antagonist . [ 164 ]
The benefit from their use is small. [ 165 ] [ 166 ]
No medication has been clearly shown to delay or halt the progression of the disease.
Reduction in the activity of the
cholinergic
neurons is a well-known feature of Alzheimer's disease. [ 167 ]
Acetylcholinesterase inhibitors are employed to reduce the rate at which
acetylcholine
(ACh) is broken down, thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons. [ 168 ]
There is evidence for the efficacy of these medications in mild to moderate Alzheimer's disease, [ 169 ] [ 170 ]
and some evidence for their use in the advanced stage. Only donepezil is approved for treatment of advanced AD dementia. [ 166 ]
The use of these drugs in
mild cognitive impairment
has not shown any effect in a delay of the onset of AD. [ 171 ]
The most common
side effects
are
nausea
and
vomiting , both of which are linked to cholinergic excess. These side effects arise in approximately 10–20% of users, are mild to moderate in severity, and can be managed by slowly adjusting medication doses. [ 172 ]
Less common secondary effects include muscle
cramps , decreased
heart rate
( bradycardia ), decreased
appetite
and weight, and increased
gastric acid
production. [ 169 ]
Glutamate
is a useful excitatory
neurotransmitter
of the
nervous system , although excessive amounts in the
brain
can lead to
cell
death through a process called
excitotoxicity
which consists of the overstimulation of glutamate
receptors . Excitotoxicity occurs not only in Alzheimer's disease, but also in other neurological diseases such as
Parkinson's disease
and
multiple sclerosis . [ 173 ]
Memantine
is a noncompetitive
NMDA receptor antagonist
first used as an anti- influenza
agent. It acts on the
glutamatergic system
by blocking
NMDA receptors
and inhibiting their overstimulation by glutamate. [ 173 ] [ 174 ]
Memantine has been shown to have a small benefit in the treatment of Alzheimer's disease. [ 175 ]
Reported adverse events with memantine are infrequent and mild, including
hallucinations ,
confusion ,
dizziness ,
headache
and
fatigue . [ 176 ]
The combination of memantine and donepezil has been shown to be "of
statistically significant
but clinically marginal effectiveness". [ 177 ]
Antipsychotic
drugs are modestly useful in reducing
aggression
and
psychosis
in Alzheimer's disease with behavioural problems, but are associated with serious adverse effects, such as
stroke ,
movement difficulties
or cognitive decline, that do not permit their routine use. [ 178 ] [ 179 ]
When used in the long-term, they have been shown to associate with increased mortality. [ 179 ]
Huperzine A
while promising, requires further evidence before it use can be recommended. [ 180 ]
Psychosocial intervention
A specifically designed room for sensory integration therapy, also called
snoezelen ; an emotion-oriented psychosocial intervention for people with dementia
Psychosocial
interventions are used as an adjunct to pharmaceutical treatment and can be classified within behaviour-, emotion-, cognition- or stimulation-oriented approaches. Research on efficacy is unavailable and rarely specific to AD, focusing instead on dementia in general. [ 181 ]
Behavioural interventions
attempt to identify and reduce the antecedents and consequences of problem behaviours. This approach has not shown success in improving overall functioning, [ 182 ]
but can help to reduce some specific problem behaviours, such as
incontinence . [ 183 ]
There is a lack of high quality data on the effectiveness of these techniques in other behaviour problems such as wandering. [ 184 ] [ 185 ]
Emotion-oriented interventions include
reminiscence therapy ,
validation therapy , supportive
psychotherapy ,
sensory integration , also called
snoezelen , and
simulated presence therapy . Supportive psychotherapy has received little or no formal scientific study, but some clinicians find it useful in helping mildly impaired people adjust to their illness. [ 181 ]
Reminiscence therapy (RT) involves the discussion of past experiences individually or in group, many times with the aid of photographs, household items, music and sound recordings, or other familiar items from the past. Although there are few quality studies on the effectiveness of RT, it may be beneficial for
cognition
and
mood . [ 186 ]
Simulated presence therapy (SPT) is based on
attachment theories
and involves playing a recording with voices of the closest relatives of the person with Alzheimer's disease. There is partial evidence indicating that SPT may reduce
challenging behaviours . [ 187 ]
Finally, validation therapy is based on acceptance of the reality and personal truth of another's experience, while sensory integration is based on exercises aimed to stimulate
senses . There is no evidence to support the usefulness of these therapies. [ 188 ] [ 189 ]
The aim of cognition-oriented treatments, which include reality orientation and
cognitive retraining , is the reduction of
cognitive deficits . Reality orientation consists in the presentation of information about time, place or person to ease the understanding of the person about its surroundings and his or her place in them. On the other hand, cognitive retraining tries to improve impaired capacities by exercitation of mental abilities. Both have shown some efficacy improving cognitive capacities, [ 190 ] [ 191 ]
although in some studies these effects were transient and negative effects, such as frustration, have also been reported. [ 181 ]
Stimulation-oriented treatments include
art ,
music
and
pet
therapies,
exercise , and any other kind of
recreational activities . Stimulation has modest support for improving behaviour, mood, and, to a lesser extent, function. Nevertheless, as important as these effects are, the main support for the use of stimulation therapies is the change in the person's routine. [ 181 ]
Caregiving
Further information:
Caregiving and dementia
Since Alzheimer's has no cure and it gradually renders people incapable of tending for their own needs, caregiving essentially is the treatment and must be carefully managed over the course of the disease.
During the early and moderate stages, modifications to the living environment and lifestyle can increase
patient safety
and reduce caretaker burden. [ 192 ] [ 193 ]
Examples of such modifications are the adherence to simplified routines, the placing of safety locks, the labelling of household items to cue the person with the disease or the use of modified daily life objects. [ 181 ] [ 194 ] [ 195 ]
If eating becomes problematic, food will need to be prepared in smaller pieces or even pureed. [ 196 ]
When
swallowing difficulties
arise, the use of
feeding tubes
may be required. In such cases, the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members. [ 197 ] [ 198 ]
The use of physical restraints is rarely indicated in any stage of the disease, although there are situations when they are necessary to prevent harm to the person with AD or their caregivers. [ 181 ]
As the disease progresses, different medical issues can appear, such as
oral and dental disease ,
pressure ulcers ,
malnutrition ,
hygiene
problems, or
respiratory ,
skin , or
eye
infections . Careful management can prevent them, while professional treatment is needed when they do arise. [ 199 ] [ 200 ]
During the final stages of the disease, treatment is centred on relieving discomfort until death, often with the help of
hospice . [ 201 ]
Feeding tubes
People with Alzheimer's disease (and other forms of
dementia ) often develop problems with eating, due to difficulties in swallowing, reduced appetite or the inability to recognise food. Their carers and families often request they have some form of
feeding tube . However, there is no evidence that this helps people with advanced Alzheimer's to gain weight, regain strength or improve their quality of life. In fact, their use might carry an increased risk of
aspiration pneumonia , use of physical restraints, and increased risk of
pressure ulcers . [ 202 ]
Prognosis
Disability-adjusted life year
for Alzheimer and other dementias per 100,000 inhabitants in 2004.
No data
≤ 50
50–70
70–90
90–110
110–130
130–150
150–170
170–190
190–210
210–230
230–250
≥ 250
The early stages of Alzheimer's disease are difficult to diagnose. A definitive diagnosis is usually made once cognitive impairment compromises daily living activities, although the person may still be living independently. The symptoms will progress from mild cognitive problems, such as memory loss through increasing stages of cognitive and non-cognitive disturbances, eliminating any possibility of independent living, especially in the late stages of the disease. [ 26 ]
Life expectancy
of the population with the disease is reduced. [ 203 ] [ 204 ] [ 205 ]
The mean life expectancy following diagnosis is approximately six years. [ 203 ]
Fewer than 3% of people live more than fourteen years. [ 206 ]
Disease features significantly associated with reduced survival are an increased severity of cognitive impairment, decreased functional level, history of falls, and disturbances in the neurological examination. Other coincident diseases such as
heart problems ,
diabetes
or history of
alcohol abuse
are also related with shortened survival. [ 204 ] [ 207 ] [ 208 ]
While the earlier the age at onset the higher the total survival years, life expectancy is particularly reduced when compared to the healthy population among those who are younger. [ 205 ]
Men have a less favourable survival prognosis than women. [ 206 ] [ 209 ]
The disease is the underlying cause of
death
in 68% of all cases. [ 203 ]
Pneumonia
and
dehydration
are the most frequent immediate causes of death brought by AD, while
cancer
is a less frequent cause of death than in the general population. [ 203 ] [ 209 ]
Epidemiology
Rates after age 65 [ 210 ]
Age
New affected
per thousand
person–years
65–69
3
70–74
6
75–79
9
80–84
23
85–89
40
90–
69
Two main measures are used in
epidemiological
studies: incidence and prevalence.
Incidence
is the number of new cases per unit of person–time at risk (usually number of new cases per thousand person–years); while
prevalence
is the total number of cases of the disease in the population at any given time.
Regarding incidence,
cohort
longitudinal studies
(studies where a disease-free population is followed over the years) provide rates between 10 and 15 per thousand person–years for all dementias and 5–8 for AD, [ 210 ] [ 211 ]
which means that half of new dementia cases each year are AD. Advancing age is a primary risk factor for the disease and incidence rates are not equal for all ages: every five years after the age of 65, the risk of acquiring the disease approximately doubles, increasing from 3 to as much as 69 per thousand person years. [ 210 ] [ 211 ]
There are also sex differences in the incidence rates, women having a higher risk of developing AD particularly in the population older than 85. [ 211 ] [ 212 ]
The risk of dying from Alzheimer's disease is twenty-six percent higher among the non-Hispanic white population than among the non-Hispanic black population, whereas the Hispanic population has a thirty percent lower risk than the non-Hispanic white population. [ 213 ]
Prevalence of AD in populations is dependent upon different factors including incidence and survival. Since the incidence of AD increases with age, it is particularly important to include the mean age of the population of interest. In the United States, Alzheimer prevalence was estimated to be 1.6% in 2000 both overall and in the 65–74 age group, with the rate increasing to 19% in the 75–84 group and to 42% in the greater than 84 group. [ 214 ]
Prevalence rates in less developed regions are lower. [ 215 ]
The
World Health Organization
estimated that in 2005, 0.379% of people worldwide had dementia, and that the prevalence would increase to 0.441% in 2015 and to 0.556% in 2030. [ 216 ]
Other studies have reached similar conclusions. [ 215 ]
Another study estimated that in 2006, 0.40% of the world population (range 0.17–0.89%; absolute number
26.6 million , range
11.4–59.4 million ) were afflicted by AD, and that the prevalence rate would triple and the absolute number would quadruple by 2050. [ 217 ]
History
Alois Alzheimer's patient
Auguste Deter
in 1902. Hers was the first described case of what became known as Alzheimer's disease.
The
ancient Greek and Roman
philosophers
and
physicians
associated old age with increasing
dementia . [ 15 ]
It was not until 1901 that German
psychiatrist
Alois Alzheimer
identified the first case of what became known as Alzheimer's disease in a fifty-year-old woman he called
Auguste D . He followed her case until she died in 1906, when he first reported publicly on it. [ 218 ]
During the next five years, eleven similar cases were reported in the
medical literature , some of them already using the term Alzheimer's disease. [ 15 ]
The disease was first described as a distinctive disease by
Emil Kraepelin
after suppressing some of the clinical (delusions and hallucinations) and pathological features (arteriosclerotic changes) contained in the original report of Auguste D. [ 219 ]
He included
Alzheimer's disease , also named
presenile
dementia
by Kraepelin, as a subtype of
senile dementia
in the eighth edition of his
Textbook of Psychiatry , published on
15 July,
1910. [ 220 ]
For most of the 20th century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia. The terminology changed after 1977 when a conference on AD concluded that the clinical and
pathological
manifestations of presenile and senile dementia were almost identical, although the authors also added that this did not rule out the possibility that they had different causes. [ 221 ]
This eventually led to the diagnosis of
Alzheimer's disease
independently of age. [ 222 ]
The term
senile dementia of the Alzheimer type
(SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used for those younger. Eventually, the term Alzheimer's disease was formally adopted in medical
nomenclature
to describe individuals of all ages with a characteristic common symptom pattern, disease course, and
neuropathology . [ 223 ]
Society and culture
Social costs
Dementia, and specifically Alzheimer's disease, may be among the most costly diseases for society in Europe and the United States, [ 16 ] [ 17 ]
while their cost in other countries such as
Argentina , [ 224 ]
or
South Korea , [ 225 ]
is also high and rising. These costs will probably increase with the ageing of society, becoming an important
social problem . AD-associated costs include direct medical costs such as
nursing
home care , direct nonmedical costs such as in-home
day care , and indirect costs such as lost
productivity
of both patient and caregiver. [ 17 ]
Numbers vary between studies but dementia costs worldwide have been calculated around $160 billion, [ 226 ]
while costs of Alzheimer's disease in the United States may be $100 billion each year. [ 17 ]
The greatest origin of costs for society is the
long-term care
by
health care professionals
and particularly
institutionalisation , which corresponds to 2/3 of the total costs for society. [ 16 ]
The cost of living
at home is also very high, [ 16 ]
especially when informal costs for the family, such as caregiving time and caregiver's lost earnings, are taken into account. [ 227 ]
Costs increase with dementia severity and the presence of behavioural disturbances, [ 228 ]
and are related to the increased caregiving time required for the provision of physical care. [ 227 ]
Therefore, any treatment that slows cognitive decline, delays institutionalisation or reduces caregivers' hours will have economic benefits. Economic evaluations of current treatments have shown positive results. [ 17 ]
Caregiving burden
Further information:
Caregiving and dementia
The role of the main
caregiver
is often taken by the spouse or a close relative. [ 229 ]
Alzheimer's disease is known for placing a great burden on
caregivers
which includes social, psychological, physical or economic aspects. [ 9 ] [ 230 ] [ 231 ]
Home care is usually preferred by people with AD and their families. [ 232 ]
This option also delays or eliminates the need for more professional and costly levels of care. [ 232 ] [ 233 ]
Nevertheless, two-thirds of nursing home residents have dementias. [ 181 ]
Dementia
caregivers are subject to high rates of physical and
mental
disorders. [ 234 ]
Factors associated with greater psychosocial problems of the primary caregivers include having an affected person at home, the carer being a spouse, demanding behaviours of the cared person such as depression, behavioural disturbances, hallucinations, sleep problems or walking disruptions and
social isolation . [ 235 ] [ 236 ]
Regarding economic problems, family caregivers often give up time from work to spend 47 hours per week on average with the person with AD, while the costs of caring for them are high. Direct and indirect costs of caring for an Alzheimer's patient average between $18,000 and $77,500 per year in the United States, depending on the study. [ 227 ] [ 229 ]
Cognitive behavioural therapy
and the teaching of
coping strategies
either individually or in group have demonstrated their efficacy in improving caregivers' psychological health. [ 9 ] [ 237 ]
Notable cases
Further information:
Alzheimer's disease in the media
See also:
Alzheimer's disease organizations
Charlton Heston
and
Ronald Reagan
at a
White House
meeting. Both would later be diagnosed with Alzheimer's disease.
As Alzheimer's disease is highly prevalent, many notable people have developed it. Well-known examples are former
United States President
Ronald Reagan
and Irish writer
Iris Murdoch , both of whom were the subjects of scientific articles examining how their cognitive capacities deteriorated with the disease. [ 238 ] [ 239 ] [ 240 ]
Other cases include the retired
footballer
Ferenc Puskás , [ 241 ]
former
Prime Ministers
Harold Wilson
(United Kingdom) and
Adolfo Suárez
( Spain ), [ 242 ] [ 243 ]
Indian politician
George Fernandes , [ 244 ]
actress
Rita Hayworth , [ 245 ]
actor
Charlton Heston , [ 246 ]
author
Harnett Kane , [ 247 ]
Nobel laureate
Charles K. Kao , [ 248 ]
novelist
Terry Pratchett , [ 249 ]
and politician and activist
Sargent Shriver . [ 250 ]
AD has also been portrayed in films such as:
Iris
(2001), based on
John Bayley 's memoir of his wife Iris Murdoch; [ 251 ]
The Notebook
(2004), based on
Nicholas Sparks ' 1996
novel of the same name ; [ 252 ]
A Moment to Remember
(2004); Thanmathra
(2005); [ 253 ]
Memories of Tomorrow (Ashita no Kioku)
(2006), based on Hiroshi Ogiwara's novel of the same name; [ 254 ]
Away from Her
(2006), based on
Alice Munro 's
short story
" The Bear Came over the Mountain "; [ 255 ]
Still Alice
(2014), about a Harvard professor who has early onset Alzheimer's disease, based on
Lisa Genova 's
2007 novel of the same name
and featuring
Julianne Moore
in the title role. Documentaries on Alzheimer's disease include
Malcolm and Barbara: A Love Story
(1999) and
Malcolm and Barbara: Love's Farewell
(2007), both featuring
Malcolm Pointon . [ 256 ]
Research directions
Main article:
Alzheimer's disease research
As of 2014 [update] , the safety and efficacy of more than 400 pharmaceutical treatments had been or were being investigated in over 1,500
clinical trials
worldwide, and approximately a quarter of these compounds are in
Phase III
trials, the last step prior to review by regulatory agencies. [ 257 ]
One area of clinical research is focused on treating the underlying disease pathology. Reduction of
beta-amyloid
levels is a common target of compounds [ 258 ]
(such as
apomorphine ) under investigation.
Immunotherapy
or
vaccination
for the amyloid protein is one
treatment modality
under study. [ 259 ]
Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed. It is based upon the concept of training
the immune system
to recognise, attack, and reverse deposition of amyloid, thereby altering the course of the disease. [ 260 ]
An example of such a vaccine under investigation was ACC-001, [ 261 ] [ 262 ]
although the trials were suspended in 2008. [ 263 ]
Another similar agent is
bapineuzumab , an antibody designed as identical to the naturally induced anti-amyloid antibody. [ 264 ]
Other approaches are neuroprotective agents, such as AL-108, [ 265 ]
and metal-protein interaction attenuation agents, such as
PBT2 . [ 266 ]
A
TNFα
receptor-blocking
fusion protein ,
etanercept
has showed encouraging results. [ 267 ]
In 2008, two separate clinical trials showed positive results in modifying the course of disease in mild to moderate AD with
methylthioninium chloride , a drug that inhibits tau aggregation, [ 268 ] [ 269 ]
and
dimebon , an
antihistamine . [ 270 ]
The consecutive phase-III trial of dimebon failed to show positive effects in the primary and secondary endpoints. [ 271 ] [ 272 ] [ 273 ]
Work with methylthioninium chloride showed that bioavailability of methylthioninium from the gut was affected by feeding and by stomach acidity, leading to unexpectedly variable dosing. [ 274 ]
A new stabilized formulation, as the
prodrug
LMTX, is in phase-III trials. [ 275 ]
The common
herpes simplex
virus HSV-1 has been found to colocate with amyloid plaques. [ 276 ]
This suggested the possibility that AD could be treated or prevented with
antiviral
medication. [ 276 ] [ 277 ]
Preliminary research on the effects of meditation on retrieving memory and cognitive functions have been encouraging. [ 278 ]
An FDA panel voted unanimously to recommend approval of
florbetapir , which is currently used in an investigational study. The imaging agent can help to detect Alzheimer's brain plaques, but will require additional clinical research before it can be made available commercially. [ 279 ]
A 2015 review suggests that
mindfulness -based interventions may prevent or delay the onset of mild cognitive impairment and Alzheimer's disease. [ 280 ]
Rare cases of possible
transmission
between people are being studied. [ 281 ] [ 282 ]
Imaging
Of the many
medical imaging
techniques available,
single photon emission computed tomography
(SPECT) appears to be superior in differentiating Alzheimer's disease from other types of dementia, and this has been shown to give a greater level of accuracy compared with mental testing and
medical history
analysis. [ 283 ]
Advances have led to the proposal of new diagnostic criteria. [ 19 ] [ 112 ]
PiB PET
remains investigational, but a similar PET scanning
radiopharmaceutical
called
florbetapir , containing the longer-lasting radionuclide
fluorine-18 , has recently been tested as a diagnostic tool in Alzheimer's disease, and given FDA approval for this use. [ 284 ] [ 285 ]
Amyloid imaging is likely to be used in conjunction with other markers rather than as an alternative. [ 286 ]
Volumetric
MRI
can detect changes in the size of brain regions. Measuring those regions that atrophy during the progress of Alzheimer's disease is showing promise as a diagnostic indicator. It may prove less expensive than other imaging methods currently under study. [ 287 ]
References
^
a
b
c
d
e
f
g
h
i
Burns A, Iliffe S (5 February 2009). "Alzheimer's disease".
BMJ
338 : b158.
doi : 10.1136/bmj.b158 .
PMID   19196745 .
^
a
b
c
d
e
"Dementia Fact sheet N°362" . World Health Organization. April 2012 . Retrieved
28 November
2014 .
^
"About Alzheimer's Disease: Symptoms" . National Institute on Aging . Retrieved
28 December
2011 .
^
a
b
Querfurth HW, LaFerla FM (28 January 2010). "Alzheimer's disease".
The New England Journal of Medicine
362
(4): 329–44.
doi : 10.1056/NEJMra0909142 .
PMID   20107219 .
^
Todd S, Barr S, Roberts M, Passmore AP (November 2013). "Survival in dementia and predictors of mortality: a review".
International Journal of Geriatric Psychiatry
28
(11): 1109–24.
doi : 10.1002/gps.3946 .
PMID   23526458 .
^
a
b
c
d
Ballard C, Gauthier S, Corbett A, et al. (19 March 2011). "Alzheimer's disease.".
Lancet
377
(9770): 1019–31.
doi : 10.1016/S0140-6736(10)61349-9 .
PMID   21371747 .
^
"Dementia diagnosis and assessment"
(PDF) . National Institute for Health and Care Excellence (NICE) . Retrieved
30 November
2014 .
^
"More research needed on ways to prevent Alzheimer's, panel finds"
(PDF) . National Institute on Aging. 29 August 2006 . Retrieved
29 February
2008 .
^
a
b
c
Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J.
Systematic Review of Information and Support Interventions for Caregivers of People with Dementia .
BMC Geriatrics . 2007;7:18.
doi : 10.1186/1471-2318-7-18 .
PMID 17662119 .
^
Forbes D, Thiessen EJ, Blake CM, Forbes SC, Forbes S (4 December 2013). "Exercise programs for people with dementia".
The Cochrane Database of Systematic Reviews
12 : CD006489.
doi : 10.1002/14651858.CD006489.pub3 .
PMID   24302466 .
^
National Institute for Health and Clinical Excellence.
"Low-dose antipsychotics in people with dementia" . National Institute for Health and Care Excellence (NICE) . Retrieved
29 November
2014 .
^
"Information for Healthcare Professionals: Conventional Antipsychotics" . US Food and Drug Administration. 16 June 2008 . Retrieved
29 November
2014 .
^
Mendez MF (November 2012). "Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD".
Archives of Medical Research
43
(8): 677–85.
doi : 10.1016/j.arcmed.2012.11.009 .
PMID   23178565 .
^
Lozano R, Naghavi M, Foreman K (15 December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.".
Lancet
380
(9859): 2095–128.
doi : 10.1016/S0140-6736(12)61728-0 .
PMID   23245604 .
^
a
b
c
Berchtold NC, Cotman CW.
Evolution in the Conceptualization of Dementia and Alzheimer's Disease: Greco-Roman Period to the 1960s.
Neurobiology of Aging . 1998;19(3):173–189.
doi : 10.1016/S0197-4580(98)00052-9 .
PMID 9661992 .
^
a
b
c
d
Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP.
Impact économique de la démence (English: The Economical Impact of Dementia).
Presse Médicale . 2005;34(1):35–41. French.
doi : 10.1016/s0755-4982(05)83882-5 .
PMID 15685097 .
^
a
b
c
d
e
Meek PD, McKeithan K, Schumock GT.
Economic Considerations in Alzheimer's Disease.
Pharmacotherapy . 1998;18(2 Pt 2):68–73; discussion 79–82.
PMID 9543467 .
^
Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price
[PDF].
Consumer Reports
Drug Effectiveness Review Project . May 2012 [Retrieved 1 May 2013]. Consumer Reports.
^
a
b
c
d
e
Waldemar G, Dubois B, Emre M, et al.
Recommendations for the Diagnosis and Management of Alzheimer's Disease and Other Disorders Associated with Dementia: EFNS Guideline.
European Journal of Neurology . 2007;14(1):e1–26.
doi : 10.1111/j.1468-1331.2006.01605.x .
PMID 17222085 .
^
a
b
c
Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ.
Multiple Cognitive Deficits During the Transition to Alzheimer's Disease.
Journal of Internal Medicine . 2004;256(3):195–204.
doi : 10.1111/j.1365-2796.2004.01386.x .
PMID 15324363 .
^
Nygård L.
Instrumental Activities of Daily Living: A Stepping-stone Towards Alzheimer's Disease Diagnosis in Subjects with Mild Cognitive Impairment?.
Acta Neurologica Scandinavica . 2003;Suppl(179):42–6.
doi : 10.1034/j.1600-0404.107.s179.8.x .
PMID 12603250 .
^
a
b
Arnáiz E, Almkvist O.
Neuropsychological Features of Mild Cognitive Impairment and Preclinical Alzheimer's Disease.
Acta Neurologica Scandinavica . 2003;179:34–41.
doi : 10.1034/j.1600-0404.107.s179.7.x .
PMID 12603249 .
^
Landes AM, Sperry SD, Strauss ME, Geldmacher DS.
Apathy in Alzheimer's Disease.
Journal of the American Geriatrics Society . 2001;49(12):1700–7.
doi : 10.1046/j.1532-5415.2001.49282.x .
PMID 11844006 .
^
Murray ED, Buttner N, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Bradley WG, Daroff RB, Fenichel GM, Jankovic J.
Bradley's neurology in clinical practice.
(6th ed.). Philadelphia, PA: Elsevier/Saunders.
ISBN   1-4377-0434-4 .
^
Grundman M, Petersen RC, Ferris SH, et al. (2004). "Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials".
Arch. Neurol.
61
(1): 59–66.
doi : 10.1001/archneur.61.1.59 .
PMID   14732621 .
^
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
Förstl H, Kurz A.
Clinical Features of Alzheimer's Disease.
European Archives of Psychiatry and Clinical Neuroscience . 1999;249(6):288–290.
doi : 10.1007/s004060050101 .
PMID 10653284 .
^
Carlesimo GA, Oscar-Berman M.
Memory Deficits in Alzheimer's Patients: A Comprehensive Review.
Neuropsychology Review . 1992;3(2):119–69.
doi : 10.1007/BF01108841 .
PMID 1300219 .
^
Jelicic M, Bonebakker AE, Bonke B.
Implicit Memory Performance of Patients with Alzheimer's Disease: A Brief Review.
International Psychogeriatrics . 1995;7(3):385–392.
doi : 10.1017/S1041610295002134 .
PMID 8821346 .
^
a
b
Taler V, Phillips NA.
Language Performance in Alzheimer's Disease and Mild Cognitive Impairment: a comparative review.
Journal of Clinical and Experimental Neuropsychology . July 2008;30(5):501–56.
doi : 10.1080/13803390701550128 .
PMID 18569251 .
^
a
b
c
Frank EM.
Effect of Alzheimer's Disease on Communication Function.
Journal of the South Carolina Medical Association . 1994;90(9):417–23.
PMID 7967534 .
^
Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A.
Sundowning and Circadian Rhythms in Alzheimer's Disease.
The American Journal of Psychiatry . 2001 [Retrieved 27 August 2008];158(5):704–11.
doi : 10.1176/appi.ajp.158.5.704 .
PMID 11329390 .
^
Gold DP, Reis MF, Markiewicz D, Andres D.
When Home Caregiving Ends: A Longitudinal Study of Outcomes for Caregivers of Relatives with Dementia.
Journal of the American Geriatrics Society . 1995;43(1):10–6.
doi : 10.1111/j.1532-5415.1995.tb06235.x .
PMID 7806732 .
^
"What We Know Today About Alzheimer's Disease" . Alzheimer's Association . Retrieved
1 October
2011 .
While scientists know Alzheimer's disease involves progressive brain cell failure, the reason cells fail isn't clear.
^
Wilson RS, Barral S, Lee JH, et al.
Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study..
Journal of Alzheimer's Disease . 2011;23(2):249–55.
doi : 10.3233/JAD-2010-101515 .
PMID 20930268 .
^
Gatz M, Reynolds CA, Fratiglioni L, et al.
Role of genes and environments for explaining Alzheimer disease.
Arch. Gen. Psychiatry . 2006;63(2):168–74.
doi : 10.1001/archpsyc.63.2.168 .
PMID 16461860 .
^
a
b
c
Blennow K, de Leon MJ, Zetterberg H.
Alzheimer's Disease.
Lancet . 2006;368(9533):387–403.
doi : 10.1016/S0140-6736(06)69113-7 .
PMID 16876668 .
^
a
b
Waring SC, Rosenberg RN.
Genome-wide association studies in Alzheimer disease.
Archives of Neurology . 2008;65(3):329–34.
doi : 10.1001/archneur.65.3.329 .
PMID 18332245 .
^
Selkoe DJ.
Translating cell biology into therapeutic advances in Alzheimer's disease.
Nature . 1999;399(6738 Suppl):A23–31.
doi : 10.1038/19866 .
PMID 10392577 .
^
Borchelt DR, Thinakaran G, Eckman CB, et al.
Familial Alzheimer's disease-linked presenilin 1 variants elevate βA1-42/1-40 ratio in vitro and in vivo
[PDF].
Neuron . 1996;17(5):1005–13.
doi : 10.1016/S0896-6273(00)80230-5 .
PMID 8938131 .
^
Shioi J, Georgakopoulos A, Mehta P, et al.
FAD mutants unable to increase neurotoxic Aβ 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta.
Journal of Neurochemistry . 2007;101(3):674–81.
doi : 10.1111/j.1471-4159.2006.04391.x .
PMID 17254019 .
^
Jonsson T, Atwal JK, Steinberg S, et al.
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline..
Nature . 2 August 2012;488(7409):96–9.
doi : 10.1038/nature11283 .
PMID 22801501 .
^
Strittmatter WJ, Saunders AM, Schmechel D, et al.
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease .
Proceedings of the National Academy of Sciences of the United States of America . 1993;90(5):1977–81.
doi : 10.1073/pnas.90.5.1977 .
PMID 8446617 .
^
a
b
Mahley RW, Weisgraber KH, Huang Y.
Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease .
Proceedings of the National Academy of Sciences of the United States of America . 2006;103(15):5644–51.
doi : 10.1073/pnas.0600549103 .
PMID 16567625 .
^
Hall K, Murrell J, Ogunniyi A, et al.
Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba .
Neurology . 2006;66(2):223–227.
doi : 10.1212/01.wnl.0000194507.39504.17 .
PMID 16434658 .
^
Gureje O, Ogunniyi A, Baiyewu O, et al.
APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians .
Annals of Neurology . 2006;59(1):182–185.
doi : 10.1002/ana.20694 .
PMID 16278853 .
^
a
b
Lambert JC (December 2013).
"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease." .
Nature Genetics
45
(12): 1452–8.
doi : 10.1038/ng.2802 .
PMC   3896259 .
PMID   24162737 .
^
Jonsson T, Stefansson H, Steinberg S, et al.
Variant of TREM2 associated with the risk of Alzheimer's disease .
The New England Journal of Medicine . 2012;368(2):107–16.
doi : 10.1056/NEJMoa1211103 .
PMID 23150908 .
^
Guerreiro R, Wojtas A, Bras J, et al.
TREM2 variants in Alzheimer's disease .
The New England Journal of Medicine . 2012;368(2):117–27.
doi : 10.1056/NEJMoa1211851 .
PMID 23150934 .
^
Francis PT, Palmer AM, Snape M, Wilcock GK.
The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress .
Journal of Neurology, Neurosurgery, and Psychiatry . 1999;66(2):137–47.
doi : 10.1136/jnnp.66.2.137 .
PMID 10071091 .
^
Shen ZX.
Brain Cholinesterases: II. The Molecular and Cellular Basis of Alzheimer's Disease.
Medical Hypotheses . 2004;63(2):308–21.
doi : 10.1016/j.mehy.2004.02.031 .
PMID 15236795 .
^
a
b
Wenk GL.
Neuropathologic Changes in Alzheimer's Disease.
The Journal of Clinical Psychiatry . 2003;64 Suppl 9:7–10.
PMID 12934968 .
^
Hardy J, Allsop D.
Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease.
Trends in Pharmacological Sciences . 1991;12(10):383–88.
doi : 10.1016/0165-6147(91)90609-V .
PMID 1763432 .
^
a
b
Mudher A, Lovestone S.
Alzheimer's disease-do tauists and baptists finally shake hands?.
Trends in Neurosciences . 2002;25(1):22–26.
doi : 10.1016/S0166-2236(00)02031-2 .
PMID 11801334 .
^
Nistor M, Don M, Parekh M, et al.
Alpha- and Beta-secretase Activity as a Function of Age and Beta-amyloid in Down Syndrome and Normal Brain .
Neurobiology of Aging . 2007;28(10):1493–1506.
doi : 10.1016/j.neurobiolaging.2006.06.023 .
PMID 16904243 .
^
Lott IT, Head E.
Alzheimer Disease and Down Syndrome: Factors in Pathogenesis.
Neurobiology of Aging . 2005;26(3):383–89.
doi : 10.1016/j.neurobiolaging.2004.08.005 .
PMID 15639317 .
^
Polvikoski T, Sulkava R, Haltia M, et al.
Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein.
The New England Journal of Medicine . 1995;333(19):1242–47.
doi : 10.1056/NEJM199511093331902 .
PMID 7566000 .
^
Transgenic mice:
Games D, Adams D, Alessandrini R, et al.
Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein.
Nature . 1995;373(6514):523–27.
doi : 10.1038/373523a0 .
PMID 7845465 .
Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D.
Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein and Alzheimer's Disease.
The Journal of Neuroscience . 1996;16(18):5795–811.
PMID 8795633 .
Hsiao K, Chapman P, Nilsen S, et al.
Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice.
Science . 1996;274(5284):99–102.
doi : 10.1126/science.274.5284.99 .
PMID 8810256 .
Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C.
Spatial Learning, Exploration, Anxiety, and Motor Coordination in Female APP23 Transgenic Mice with the Swedish Mutation.
Brain Research . 2002;956(1):36–44.
doi : 10.1016/S0006-8993(02)03476-5 .
PMID 12426044 .
^
Holmes C, Boche D, Wilkinson D, et al.
Long-term Effects of Abeta42 Immunisation in Alzheimer's Disease: Follow-up of a Randomised, Placebo-controlled Phase I Trial.
Lancet . 2008;372(9634):216–23.
doi : 10.1016/S0140-6736(08)61075-2 .
PMID 18640458 .
^
Lacor PN, Buniel MC, Furlow PW, et al.
Aß Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease.
The Journal of Neuroscience . 2007;27(4):796–807.
doi : 10.1523/JNEUROSCI.3501-06.2007 .
PMID 17251419 .
^
Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM.
Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers .
Nature . 2009;457(7233):1128–32.
doi : 10.1038/nature07761 .
PMID 19242475 .
^
Jaunmuktane, Z; Mead, S; Ellis, M; Wadsworth, JD; Nicoll, AJ; Kenny, J; Launchbury, F; Linehan, J; Richard-Loendt, A; Walker, AS; Rudge, P; Collinge, J; Brandner, S (10 September 2015). "Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.".
Nature
525
(7568): 247–50.
doi : 10.1038/nature15369 .
PMID   26354483 .
^
a
b
Nikolaev A, McLaughlin T, O'Leary DD,
Tessier-Lavigne M .
APP Binds DR6 to Cause Axon Pruning and Neuron Death via Distinct Caspases .
Nature . 19 February 2009;457(7232):981–989.
doi : 10.1038/nature07767 .
PMID 19225519 .
^
Goedert M, Spillantini MG, Crowther RA.
Tau Proteins and Neurofibrillary Degeneration.
Brain Pathology . 1991;1(4):279–86.
doi : 10.1111/j.1750-3639.1991.tb00671.x .
PMID 1669718 .
^
Iqbal K, Alonso Adel C, Chen S, et al.
Tau Pathology in Alzheimer Disease and Other Tauopathies.
Biochimica et Biophysica Acta . 2005;1739(2–3):198–210.
doi : 10.1016/j.bbadis.2004.09.008 .
PMID 15615638 .
^
Chun W, Johnson GV.
The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death.
Frontiers in Bioscience . 2007;12:733–56.
doi : 10.2741/2097 .
PMID 17127334 .
^
Deane, R; Zlokovic, BV (April 2007). "Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.".
Current Alzheimer research
4
(2): 191–7.
PMID   17430246 .
^
Itzhaki RF, Wozniak MA.
Herpes Simplex Virus Type 1 in Alzheimer's Disease: The Enemy Within .
Journal of Alzheimer's Disease . 2008 [Retrieved 5 February 2011];13(4):393–405.
PMID 18487848 .
^
Xu H, Finkelstein DI, Adlard PA.
Interactions of metals and Apolipoprotein E in Alzheimer's disease .
Frontiers Aging Neuroscience . 12 June 2014;6:121.
doi : 10.3389/fnagi.2014.00121 .
PMID 24971061 . "Although we still do not know if the metal ion dyshomeostasis present in AD is a cause or consequence of the disease, there is a growing body of evidence showing a direct correlation between metal ions and key AD-related key proteins."
^
Shcherbatykh I, Carpenter DO.
The Role of Metals in the Etiology of Alzheimer's Disease.
Journal of Alzheimer's Disease . 2007;11(2):191–205.
PMID 17522444 .
^
Santibáñez M, Bolumar F, García AM.
Occupational Risk Factors in Alzheimer's Disease: A Review Assessing the Quality of Published Epidemiological Studies .
Occupational and Environmental Medicine . 2007;64(11):723–732.
doi : 10.1136/oem.2006.028209 .
PMID 17525096 .
^
Lidsky, TI (May 2014). "Is the Aluminum Hypothesis dead?".
Journal of Occupational and Environmental Medicine
56
(5 Suppl): S73–9.
doi : 10.1097/jom.0000000000000063 .
PMID   24806729 .
^
Rondeau V.
A Review of Epidemiologic Studies on Aluminum and Silica in Relation to Alzheimer's Disease and Associated Disorders.
Reviews on Environmental Health . 2002;17(2):107–21.
doi : 10.1515/REVEH.2002.17.2.107 .
PMID 12222737 .
^
Brewer GJ.
Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease.
BioFactors . March 2012;38(2):107–113.
doi : 10.1002/biof.1005 .
PMID 22438177 .
^
Kheifets L, Bowman JD, Checkoway H, et al.
Future needs of occupational epidemiology of extremely low frequency electric and magnetic fields: review and recommendations.
Occupational and Environmental Medicine . February 2009;66(2):72–80.
doi : 10.1136/oem.2007.037994 .
PMID 18805878 .
^
Scientific Committee on Emerging and Newly Identified Health Risks-SCENIHR.
Health Effects of Exposure to EMF . January 2009 [Retrieved 27 April 2010]:4–5.
^
Cataldo JK, Prochaska JJ, Glantz SA.
Cigarette smoking is a risk factor for Alzheimer's disease: An analysis controlling for tobacco industry affiliation .
Journal of Alzheimer's Disease . 2010;19(2):465–80.
doi : 10.3233/JAD-2010-1240 .
PMID 20110594 .
^
Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA.
Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer's Disease.
Neuro-Degenerative Diseases . 2010;7(1–3):38–41.
doi : 10.1159/000283480 .
PMID 20160456 .
^
Bartzokis G.
Alzheimer's Disease as Homeostatic Responses to Age-related Myelin Breakdown .
Neurobiology of Aging . August 2011;32(8):1341–71.
doi : 10.1016/j.neurobiolaging.2009.08.007 .
PMID 19775776 .
^
Bartzokis G, Lu PH, Mintz J.
Quantifying Age-Related Myelin Breakdown with MRI: Novel Therapeutic Targets for Preventing Cognitive Decline and Alzheimer's Disease.
Journal of Alzheimer's Disease . December 2004;6(6 Suppl):S53–9.
PMID 15665415 .
^
Bartzokis G, Lu PH, Mintz J.
Human Brain Myelination and Beta-amyloid Deposition in Alzheimer's Disease .
Alzheimer's & Dementia . April 2007;3(2):122–5.
doi : 10.1016/j.jalz.2007.01.019 .
PMID 18596894 .
^
Su B, Wang X, Nunomura A, et al.
Oxidative Stress Signaling in Alzheimer's Disease .
Current Alzheimer Research . December 2008;5(6):525–32.
doi : 10.2174/156720508786898451 .
PMID 19075578 .
^
Kastenholz B, Garfin DE, Horst J, Nagel KA.
Plant Metal Chaperones: A Novel Perspective in Dementia Therapy.
Amyloid: The International Journal of Experimental and Clinical Investigation . 2009;16(2):81–3.
doi : 10.1080/13506120902879392 .
PMID 20536399 .
^
Pohanka M.
Alzheimer´s Disease and Oxidative Stress: A Review.
Current Medicinal Chemistry . 2013;21(3):356–64.
doi : 10.2174/09298673113206660258 .
PMID 24059239 .
^
Pohanka M (2011). "Alzheimer´s disease and related neurodegenerative disorders: implication and counteracting of melatonin".
Journal of Applied Biomedicine
9 : 185–196.
doi : 10.2478/v10136-011-0003-6 .
^
a
b
c
Heneka MT, Nadrigny F, Regen T, et al. (2010).
"Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine"
(PDF) .
Proceedings of the National Academy of Sciences of the United States of America
107
(13): 6058–6063.
doi : 10.1073/pnas.0909586107 .
PMC   2851853 .
PMID   20231476 .
^
Moulton PV, Yang W.
Air Pollution, Oxidative Stress, and Alzheimer's Disease.
Journal of Environmental and Public Health . 2012;2012:472751.
doi : 10.1155/2012/472751 .
PMID 22523504 .
^
Braak H, Del Tredici K.
Where, when, and in what form does sporadic Alzheimer's disease begin?.
Current Opinion in Neurology . December 2012;25(Pt 6):708–14.
doi : 10.1097/WCO.0b013e32835a3432 .
PMID 23160422 .
^
Desikan RS, Cabral HJ, Hess CP, et al.
Automated MRI Measures Identify Individuals with Mild Cognitive Impairment and Alzheimer's Disease .
Brain . August 2009;132(Pt 8):2048–57.
doi : 10.1093/brain/awp123 .
PMID 19460794 .
^
Moan R.
MRI Software Accurately IDs Preclinical Alzheimer's Disease .
Diagnostic Imaging . 20 July 2009.
^
a
b
Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J.
The Importance of Neuritic Plaques and Tangles to the Development and Evolution of AD.
Neurology . 2004;62(11):1984–9.
doi : 10.1212/01.WNL.0000129697.01779.0A .
PMID 15184601 .
^
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH.
Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Elderly Patients: A Quantitative Evaluation of a One-year Autopsy Population from a Geriatric Hospital.
Cerebral Cortex . 1994;4(2):138–50.
doi : 10.1093/cercor/4.2.138 .
PMID 8038565 .
^
Kotzbauer PT, Trojanowsk JQ, Lee VM.
Lewy Body Pathology in Alzheimer's Disease.
Journal of Molecular Neuroscience . 2001;17(2):225–32.
doi : 10.1385/JMN:17:2:225 .
PMID 11816795 .
^
Hashimoto M, Rockenstein E, Crews L, Masliah E.
Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases.
Neuromolecular Medicine . 2003;4(1–2):21–36.
doi : 10.1385/NMM:4:1-2:21 .
PMID 14528050 .
^
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J.
Synapse Formation and Function is Modulated by the Amyloid Precursor Protein.
The Journal of Neuroscience . 2006;26(27):7212–21.
doi : 10.1523/JNEUROSCI.1450-06.2006 .
PMID 16822978 .
^
Turner PR, O'Connor K, Tate WP, Abraham WC.
Roles of Amyloid Precursor Protein and its Fragments in Regulating Neural Activity, Plasticity and Memory.
Progress in Neurobiology . 2003;70(1):1–32.
doi : 10.1016/S0301-0082(03)00089-3 .
PMID 12927332 .
^
Hooper NM.
Roles of Proteolysis and Lipid Rafts in the Processing of the Amyloid Precursor Protein and Prion Protein.
Biochemical Society Transactions . 2005;33(Pt 2):335–8.
doi : 10.1042/BST0330335 .
PMID 15787600 .
^
Ohnishi S, Takano K.
Amyloid Fibrils from the Viewpoint of Protein Folding.
Cellular and Molecular Life Sciences . 2004;61(5):511–24.
doi : 10.1007/s00018-003-3264-8 .
PMID 15004691 .
^
Hernández F, Avila J.
Tauopathies.
Cellular and Molecular Life Sciences . 2007;64(17):2219–33.
doi : 10.1007/s00018-007-7220-x .
PMID 17604998 .
^
Van Broeck B, Van Broeckhoven C, Kumar-Singh S.
Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches.
Neuro-Degenerative Diseases . 2007;4(5):349–65.
doi : 10.1159/000105156 .
PMID 17622778 .
^
Huang Y, Mucke L.
Alzheimer Mechanisms and Therapeutic strategies.
Cell . 2012;148(6):1204–22.
doi : 10.1016/j.cell.2012.02.040 .
PMID 22424230 .
^
Yankner BA, Duffy LK, Kirschner DA.
Neurotrophic and Neurotoxic Effects of Amyloid Beta Protein: Reversal by Tachykinin Neuropeptides.
Science . 1990;250(4978):279–82.
doi : 10.1126/science.2218531 .
PMID 2218531 .
^
Chen X, Yan SD.
Mitochondrial Abeta: A Potential Cause of Metabolic Dysfunction in Alzheimer's Disease.
IUBMB Life . 2006;58(12):686–94.
doi : 10.1080/15216540601047767 .
PMID 17424907 .
^
Greig NH, Mattson MP, Perry T, et al.
New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-alpha Inhibitors, and GLP-1 Receptor Agonists.
Annals of the New York Academy of Sciences . 2004;1035:290–315.
doi : 10.1196/annals.1332.018 .
PMID 15681814 .
^
Heneka MT (April 2015). "Neuroinflammation in Alzheimer's disease".
Lancet Neurology
14
(4): 388–405.
doi : 10.1016/S1474-4422(15)70016-5 .
PMID   25792098 .
^
Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S.
New insights into brain BDNF function in normal aging and Alzheimer disease.
Brain Research Reviews . 2008;59(1):201–20.
doi : 10.1016/j.brainresrev.2008.07.007 .
PMID 18708092 .
^
Schindowski K, Belarbi K, Buée L.
Neurotrophic factors in Alzheimer's disease: role of axonal transport .
Genes, Brain, and Behavior . 2008;7(Suppl 1):43–56.
doi : 10.1111/j.1601-183X.2007.00378.x .
PMID 18184369 .
^
Mendez MF.
The Accurate Diagnosis of Early-onset Dementia.
International Journal of Psychiatry in Medicine . 2006;36(4):401–412.
doi : 10.2190/Q6J4-R143-P630-KW41 .
PMID 17407994 .
^
Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J.
Therapeutic Approaches to Alzheimer's Disease.
Brain . 2006;129(Pt 11):2840–55.
doi : 10.1093/brain/awl280 .
PMID 17018549 .
^
Dementia: Quick Reference Guide
(PDF) . London: (UK)
National Institute for Health and Clinical Excellence . November 2006.
ISBN   1-84629-312-X .
Archived
(PDF)
from the original on 27 February 2008 . Retrieved
22 February
2008 .
^
Schroeter ML, Stein T, Maslowski N, Neumann J.
Neural Correlates of Alzheimer's Disease and Mild Cognitive Impairment: A Systematic and Quantitative Meta-Analysis involving 1,351 Patients .
NeuroImage . 2009;47(4):1196–1206.
doi : 10.1016/j.neuroimage.2009.05.037 .
PMID 19463961 .
^
a
b
McKhann G, Drachman D, Folstein M, et al.
Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
Neurology . 1984;34(7):939–44.
doi : 10.1212/wnl.34.7.939 .
PMID 6610841 .
^
a
b
Dubois B, Feldman HH, Jacova C, et al.
Research Criteria for the Diagnosis of Alzheimer's Disease: Revising the NINCDS-ADRDA Criteria.
Lancet Neurology . 2007;6(8):734–46.
doi : 10.1016/S1474-4422(07)70178-3 .
PMID 17616482 .
^
Blacker D, Albert MS, Bassett SS, et al.
Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative.
Archives of Neurology . 1994;51(12):1198–204.
doi : 10.1001/archneur.1994.00540240042014 .
PMID 7986174 .
^
American Psychiatric Association (2000).
Diagnostic and statistical manual of mental disorders: DSM-IV-TR
(4th Edition Text Revision ed.). Washington, DC: American Psychiatric Association.
ISBN   0-89042-025-4 .
^
Ito N.
[Clinical aspects of dementia].
Hokkaido Igaku Zasshi . 1996;71(3):315–20. Japanese.
PMID 8752526 .
^
Tombaugh TN, McIntyre NJ.
The mini-mental state examination: a comprehensive review.
Journal of the American Geriatrics Society . 1992;40(9):922–35.
doi : 10.1111/j.1532-5415.1992.tb01992.x .
PMID 1512391 .
^
Pasquier F.
Early diagnosis of dementia: neuropsychology.
Journal of Neurology . 1999;246(1):6–15.
doi : 10.1007/s004150050299 .
PMID 9987708 .
^
Harvey PD, Moriarty PJ, Kleinman L, et al.
The Validation of a Caregiver Assessment of Dementia: the Dementia Severity Scale.
Alzheimer Disease and Associated Disorders . 2005;19(4):186–94.
doi : 10.1097/01.wad.0000189034.43203.60 .
PMID 16327345 .
^
Antoine C, Antoine P, Guermonprez P, Frigard B.
Awareness of Deficits and Anosognosia in Alzheimer's Disease.
L'Encéphale . 2004;30(6):570–7. French.
doi : 10.1016/S0013-7006(04)95472-3 .
PMID 15738860 .
^
Cruz VT, Pais J, Teixeira A, Nunes B.
The Initial Symptoms of Alzheimer Disease: Caregiver Perception.
Acta Médica Portuguesa . 2004;17(6):435–44. Portuguese.
PMID 16197855 .
^
Clarfield AM.
The Decreasing Prevalence of Reversible Dementias: An Updated Meta-analysis.
Archives of Internal Medicine . 2003;163(18):2219–29.
doi : 10.1001/archinte.163.18.2219 .
PMID 14557220 .
^
Sun X, Steffens DC, Au R, et al.
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease? .
Archives of General Psychiatry . 2008;65(5):542–550.
doi : 10.1001/archpsyc.65.5.542 .
PMID 18458206 .
PMC
3042807 .
^
Geldmacher DS, Whitehouse PJ.
Differential Diagnosis of Alzheimer's Disease.
Neurology . 1997;48(5 Suppl 6):S2–9.
doi : 10.1212/WNL.48.5_Suppl_6.2S .
PMID 9153154 .
^
Potter GG, Steffens DC.
Contribution of Depression to Cognitive Impairment and Dementia in Older adults.
The Neurologist . 2007;13(3):105–17.
doi : 10.1097/01.nrl.0000252947.15389.a9 .
PMID 17495754 .
^
Chong MS, Sahadevan S.
Preclinical Alzheimer's disease: diagnosis and prediction of progression .
Lancet Neurology . 1 September 2005 [Retrieved 7 April 2014];4(9):576–9.
doi : 10.1016/s1474-4422(05)70168-x .
PMID 16109364 .
^
Marksteiner J, Hinterhuber H, Humpel C.
Cerebrospinal Fluid Biomarkers for Diagnosis of Alzheimer's Disease: Beta-amyloid(1–42), Tau, Phospho-tau-181 and Total Protein.
Drugs of Today . 2007;43(6):423–31.
doi : 10.1358/dot.2007.43.6.1067341 .
PMID 17612711 .
^
a
b
c
De Meyer G, Shapiro F, Vanderstichele H, et al.
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People .
Archives of Neurology . 2010;67(8):949–56.
doi : 10.1001/archneurol.2010.179 .
PMID 20697045 .
^
Sui X, Liu J, Yang X (2014). "Cerebrospinal fluid biomarkers of Alzheimer's disease".
Neuroscience Bulletin
(Review)
30
(2): 233–42.
doi : 10.1007/s12264-013-1412-1 .
PMID   24733653 .
^
Prevention recommendations not supported:
Kawas CH.
Medications and Diet: Protective Factors for AD?.
Alzheimer Disease and Associated Disorders . 2006;20(3 Suppl 2):S89–96.
doi : 10.1097/00002093-200607001-00014 .
PMID 16917203 .
Luchsinger JA, Mayeux R.
Dietary Factors and Alzheimer's Disease.
Lancet Neurology . 2004;3(10):579–87.
doi : 10.1016/S1474-4422(04)00878-6 .
PMID 15380154 .
Luchsinger JA, Noble JM, Scarmeas N.
Diet and Alzheimer's Disease.
Current Neurology and Neuroscience Reports . 2007;7(5):366–72.
doi : 10.1007/s11910-007-0057-8 .
PMID 17764625 .
"Independent Panel Finds Insufficient Evidence to Support Preventive Measures for Alzheimer's Disease"
(Press release).
National Institutes of Health . 28 April 2010.
Daviglus ML, et al. (26–28 April 2010).
"NIH State-of-the-Science Conference: Preventing Alzheimer's Disease and Cognitive Decline" .
^
Szekely CA, Breitner JC, Zandi PP.
Prevention of Alzheimer's Disease.
International Review of Psychiatry . 2007;19(6):693–706.
doi : 10.1080/09540260701797944 .
PMID 18092245 .
^
Patterson C, Feightner JW, Garcia A, et al.
Diagnosis and Treatment of Dementia: 1. Risk Assessment and Primary Prevention of Alzheimer Disease .
Canadian Medical Association Journal . 2008;178(5):548–56.
doi : 10.1503/cmaj.070796 .
PMID 18299540 .
^
Rosendorff C, Beeri MS, Silverman JM.
Cardiovascular Risk Factors for Alzheimer's Disease.
The American Journal of Geriatric Cardiology . 2007;16(3):143–9.
doi : 10.1111/j.1076-7460.2007.06696.x .
PMID 17483665 .
^
Reiss AB, Wirkowski E.
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders: Progress to Date.
Drugs . 2007;67(15):2111–20.
doi : 10.2165/00003495-200767150-00001 .
PMID 17927279 .
^
Kuller LH.
Statins and Dementia.
Current Atherosclerosis Reports . 2007;9(2):154–61.
doi : 10.1007/s11883-007-0012-9 .
PMID 17877925 .
^
McGuinness, B; Craig, D; Bullock, R; Malouf, R; Passmore, P (8 July 2014). "Statins for the treatment of dementia.".
The Cochrane Database of Systematic Reviews
7 : CD007514.
doi : 10.1002/14651858.CD007514.pub3 .
PMID   25004278 .
^
a
b
c
Szekely CA, Town T, Zandi PP.
NSAIDs for the Chemoprevention of Alzheimer's Disease.
Sub-Cellular Biochemistry . 2007;42:229–48.
doi : 10.1007/1-4020-5688-5_11 .
PMID 17612054 .
^
Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P (February 2011). "Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology".
CNS & Neurological Disorders Drug Targets
10
(1): 57–67.
doi : 10.2174/187152711794488665 .
PMID   21143138 .
^
Marjoribanks J, Farquhar C, Roberts H, Lethaby A.
Long term hormone therapy for perimenopausal and postmenopausal women.
The Cochrane Database of Systematic Reviews . 2012;7:CD004143.
doi : 10.1002/14651858.CD004143.pub4 .
PMID 22786488 .
^
a
b
Stern Y.
Cognitive reserve and Alzheimer disease.
Alzheimer Disease and Associated Disorders . July 2006;20(2):112–117.
doi : 10.1097/01.wad.0000213815.20177.19 .
PMID 16917199 .
^
a
b
Paradise M, Cooper C, Livingston G.
Systematic Review of the Effect of Education on Survival in Alzheimer's Disease.
International Psychogeriatrics . 2009;21(1):25–32.
doi : 10.1017/S1041610208008053 .
PMID 19026089 .
^
Neergaard, Lauran (19 February 2011).
"Speaking 2 Languages May Delay Getting Alzheimer's" . The Denver Post. Associated Press.
^
a
b
Hu N, Yu JT, Tan L, et al.
Nutrition and the Risk of Alzheimer's Disease.
BioMed Research International . 2013;2013.
doi : 10.1155/2013/524820 . 524820.
^
Solfrizzi V, Panza F, Frisardi V, et al.
Diet and Alzheimer's disease risk factors or prevention: the current evidence.
Expert Review of Neurotherapeutics . May 2011;11(5):677–708.
doi : 10.1586/ern.11.56 .
PMID 21539488 .
^
Kanoski SE, Davidson TL.
Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity .
Physiology & Behavior . 18 April 2011;103(1):59–68.
doi : 10.1016/j.physbeh.2010.12.003 .
PMID 21167850 .
^
Solfrizzi V, Capurso C, D'Introno A, et al.
Lifestyle-related Factors in Predementia and Dementia Syndromes.
Expert Review of Neurotherapeutics . 2008;8(1):133–58.
doi : 10.1586/14737175.8.1.133 .
PMID 18088206 .
^
Panza F, Capurso C, D'Introno A, et al.
Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes.
Journal of Alzheimer's Disease . May 2009;17(1):7–31.
doi : 10.3233/JAD-2009-1009 .
PMID 19494429 .
^
Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N.
Caffeine intake and dementia: systematic review and meta-analysis.
Journal of Alzheimer's Disease . 2010;20 Suppl 1:S187–204.
doi : 10.3233/JAD-2010-091387 .
PMID 20182026 .
^
Nehlig A.
The neuroprotective effects of cocoa flavanol and its influence on cognitive performance.
British Journal of Clinical Pharmacology . July 2012;75(3):n/a–n/a.
doi : 10.1111/j.1365-2125.2012.04378.x .
PMID 22775434 .
^
Stoclet JC, Schini-Kerth V.
[Dietary flavonoids and human health].
Annales Pharmaceutiques Françaises . March 2011;69(2):78–90.
doi : 10.1016/j.pharma.2010.11.004 .
PMID 21440100 .
^
Ono K, Yamada M.
Vitamin A and Alzheimer's disease.
Geriatrics & Gerontology International . April 2012;12(2):180–8.
doi : 10.1111/j.1447-0594.2011.00786.x .
PMID 22221326 .
^
Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G.
Retinoids for treatment of Alzheimer's disease.
BioFactors . Mar–April 2012;38(2):84–9.
doi : 10.1002/biof.196 .
PMID 22419567 .
^
Heo JH, Lee KM.
The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention.
American Journal of Alzheimer's Disease and Other Dementias . March 2013;28(2):120–5.
doi : 10.1177/1533317512473193 .
PMID 23307795 .
^
a
b
c
Boothby LA, Doering PL.
Vitamin C and Vitamin E for Alzheimer's Disease.
The Annals of Pharmacotherapy . 2005;39(12):2073–80.
doi : 10.1345/aph.1E495 .
PMID 16227450 .
^
Farina, N; Isaac, MG; Clark, AR; Rusted, J; Tabet, N (14 November 2012). "Vitamin E for Alzheimer's dementia and mild cognitive impairment.".
The Cochrane Database of Systematic Reviews
11 : CD002854.
doi : 10.1002/14651858.CD002854.pub3 .
PMID   23152215 .
^
Loef M, Schrauzer GN, Walach H.
Selenium and Alzheimer's disease: a systematic review.
Journal of Alzheimer's Disease . 2011;26(1):81–104.
doi : 10.3233/JAD-2011-110414 .
PMID 21593562 .
^
Loef M, von Stillfried N, Walach H.
Zinc diet and Alzheimer's disease: a systematic review.
Nutritional Neuroscience . 1 September 2012;15(5):2–12.
doi : 10.1179/1476830512Y.0000000010 .
PMID 22583839 .
^
Malouf R, Grimley Evans J.
Folic Acid with or without Vitamin B 12
for the Prevention and Treatment of Healthy Elderly and Demented people.
The Cochrane Database of Systematic Reviews . 2008;(4):CD004514.
doi : 10.1002/14651858.CD004514.pub2 .
PMID 18843658 .
^
Wald DS, Kasturiratne A, Simmonds M.
Effect of Folic Acid, with or without other B vitamins, on Cognitive Decline: Meta-analysis of Randomized trials.
The American Journal of Medicine . June 2010;123(6):522–527.e2.
doi : 10.1016/j.amjmed.2010.01.017 .
PMID 20569758 .
^
Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P.
Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?.
Prostaglandins, Leukotrienes, and Essential Fatty Acids . January 2013;88(1):61–70.
doi : 10.1016/j.plefa.2012.04.006 .
PMID 22575581 .
^
Hamaguchi T, Ono K, Yamada M.
REVIEW: Curcumin and Alzheimer's disease.
CNS Neuroscience & Therapeutics . October 2010;16(5):285–97.
doi : 10.1111/j.1755-5949.2010.00147.x .
PMID 20406252 .
^
Birks J, Grimley Evans J.
Ginkgo Biloba for Cognitive Impairment and Dementia.
The Cochrane Database of Systematic Reviews . 2009;(1):CD003120.
doi : 10.1002/14651858.CD003120.pub3 .
PMID 19160216 .
^
Krishnan S, Cairns R, Howard R.
Cannabinoids for the treatment of dementia.
The Cochrane Database of Systematic Reviews . 2009;(2):CD007204.
doi : 10.1002/14651858.CD007204.pub2 .
PMID 19370677 .
^
Bilkei-Gorzo A.
The endocannabinoid system in normal and pathological brain ageing .
Philosophical Transactions of the Royal Society of London B . 2012;367(1607):3326–41.
doi : 10.1098/rstb.2011.0388 .
PMID 23108550 .
^
Pohanka M.
Cholinesterases, a target of pharmacology and toxicology .
Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic . 2011;155(3):219–229.
doi : 10.5507/bp.2011.036 .
PMID 22286807 .
^
Commission de la transparence.
Médicaments de la maladie d'Alzheimer [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage].
Prescrire International . June 2012;21(128):150.
PMID 22822592 .
^
a
b
Birks J, Harvey RJ.
Donepezil for dementia due to Alzheimer's disease.
The Cochrane Database of Systematic Reviews . 25 January 2006;(1):CD001190.
doi : 10.1002/14651858.CD001190.pub2 .
PMID 16437430 .
^
Geula C, Mesulam MM.
Cholinesterases and the pathology of Alzheimer disease.
Alzheimer Disease and Associated Disorders . 1995;9 Suppl 2:23–28.
doi : 10.1097/00002093-199501002-00005 .
PMID 8534419 .
^
Stahl SM.
The new cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action.
The Journal of Clinical Psychiatry . 2000;61(11):813–814.
doi : 10.4088/JCP.v61n1101 .
PMID 11105732 .
^
a
b
Birks J.
Cholinesterase inhibitors for Alzheimer's disease.
The Cochrane Database of Systematic Reviews . 2006;(1):CD005593.
doi : 10.1002/14651858.CD005593 .
PMID 16437532 .
^
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.
Rivastigmine for Alzheimer's disease.
The Cochrane Database of Systematic Reviews . 15 April 2009;(2):CD001191.
doi : 10.1002/14651858.CD001191.pub2 .
PMID 19370562 .
^
Raschetti R, Albanese E, Vanacore N, Maggini M.
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials .
PLoS Medicine . 2007;4(11):e338.
doi : 10.1371/journal.pmed.0040338 .
PMID 18044984 .
^
al.], edited by Brian K. Alldredge ... [et (2013).
Applied therapeutics : the clinical use of drugs
(10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 2385.
ISBN   978-1609137137 .
^
a
b
Lipton SA.
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Nature Reviews. Drug Discovery . 2006;5(2):160–170.
doi : 10.1038/nrd1958 .
PMID 16424917 .
^
"Memantine" . US National Library of Medicine (Medline). 4 January 2004.
Archived
from the original on 22 February 2010 . Retrieved
3 February
2010 .
^
McShane, R; Areosa Sastre, A; Minakaran, N (19 April 2006). "Memantine for dementia.".
The Cochrane Database of Systematic Reviews
(2): CD003154.
doi : 10.1002/14651858.CD003154.pub5 .
PMID   16625572 .
^
"Namenda prescribing information"
(PDF) .
Forest Pharmaceuticals .
Archived
(PDF)
from the original on 27 February 2008 . Retrieved
19 February
2008 .
(primary source)
^
Raina P, Santaguida P, Ismaila A, et al.
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Annals of Internal Medicine . 2008;148(5):379–397.
doi : 10.7326/0003-4819-148-5-200803040-00009 .
PMID 18316756 .
^
Antipsychotics use:
Ballard C, Waite J.
The Effectiveness of Atypical Antipsychotics for the Treatment of Aggression and Psychosis in Alzheimer's Disease.
The Cochrane Database of Systematic Reviews . 2006;(1):CD003476.
doi : 10.1002/14651858.CD003476.pub2 .
PMID 16437455 .
Ballard C, Lana MM, Theodoulou M, et al.
A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial) .
PLoS Medicine . 2008;5(4):e76.
doi : 10.1371/journal.pmed.0050076 .
PMID 18384230 .
Sink KM, Holden KF, Yaffe K.
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence.
JAMA . 2005;293(5):596–608.
doi : 10.1001/jama.293.5.596 .
PMID 15687315 .
^
a
b
Ballard C, Hanney ML, Theodoulou M, et al.
The Dementia Antipsychotic Withdrawal Trial (DART-AD): Long-term Follow-up of a Randomised Placebo-controlled Trial.
Lancet Neurology . 9 January 2009;8(2):151–7.
doi : 10.1016/S1474-4422(08)70295-3 .
PMID 19138567 .
Lay summary .
^
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR.
Huperzine A for Alzheimer's disease .
The Cochrane Database of Systematic Reviews . 2008;(2):CD005592.
doi : 10.1002/14651858.CD005592.pub2 .
PMID 18425924 .
^
a
b
c
d
e
f
g
Rabins PV, Blacker D, Rovner BW, et al.
American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias.
The American Journal of Psychiatry . December 2007;164(12 Suppl):5–56.
PMID 18340692 .
^
Bottino CM, Carvalho IA, Alvarez AM, et al.
Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study.
Clinical Rehabilitation . 2005;19(8):861–869.
doi : 10.1191/0269215505cr911oa .
PMID 16323385 .
^
Doody RS, Stevens JC, Beck C, et al.
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology . 2001;56(9):1154–1166.
doi : 10.1212/WNL.56.9.1154 .
PMID 11342679 .
^
Hermans DG, Htay UH, McShane R.
Non-pharmacological interventions for wandering of people with dementia in the domestic setting.
The Cochrane Database of Systematic Reviews . 2007;(1):CD005994.
doi : 10.1002/14651858.CD005994.pub2 .
PMID 17253573 .
^
Robinson L, Hutchings D, Dickinson HO, et al.
Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review.
International Journal of Geriatric Psychiatry . 2007;22(1):9–22.
doi : 10.1002/gps.1643 .
PMID 17096455 .
^
Woods B, Spector A, Jones C, Orrell M, Davies S.
Reminiscence therapy for dementia.
The Cochrane Database of Systematic Reviews . 2005;(2):CD001120.
doi : 10.1002/14651858.CD001120.pub2 .
PMID 15846613 .
^
Zetteler J.
Effectiveness of simulated presence therapy for individuals with dementia: a systematic review and meta-analysis.
Aging & Mental Health . November 2008;12(6):779–85.
doi : 10.1080/13607860802380631 .
PMID 19023729 .
^
Neal M, Briggs M.
Validation therapy for dementia.
The Cochrane Database of Systematic Reviews . 2003;(3):CD001394.
doi : 10.1002/14651858.CD001394 .
PMID 12917907 .
^
Chung JC, Lai CK, Chung PM, French HP.
Snoezelen for dementia.
The Cochrane Database of Systematic Reviews . 2002;(4):CD003152.
doi : 10.1002/14651858.CD003152 .
PMID 12519587 .
(up to date as of 2009)
^
Spector A, Orrell M, Davies S, Woods B.
Withdrawn: reality orientation for dementia.
The Cochrane Database of Systematic Reviews . 2000;(3):CD001119.
doi : 10.1002/14651858.CD001119.pub2 .
PMID 17636652 .
^
Spector A, Thorgrimsen L, Woods B, et a;.
Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial.
The British Journal of Psychiatry . 2003;183(3):248–254.
doi : 10.1192/bjp.183.3.248 .
PMID 12948999 .
^
Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW.
A Randomized, Controlled Trial of a Home Environmental Intervention: Effect on Efficacy and Upset in Caregivers and on Daily Function of Persons with Dementia .
The Gerontologist . 1 February 2001 [Retrieved 15 July 2008];41(1):4–14.
doi : 10.1093/geront/41.1.4 .
PMID 11220813 .
^
Gitlin LN, Hauck WW, Dennis MP, Winter L.
Maintenance of Effects of the Home Environmental Skill-building Program for Family Caregivers and Individuals with Alzheimer's Disease and Related Disorders.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 2005;60(3):368–74.
doi : 10.1093/gerona/60.3.368 .
PMID 15860476 .
^
"Treating Behavioral and Psychiatric Symptoms" . Alzheimer's Association. 2006. Archived from
the original
on 25 September 2006 . Retrieved
25 September
2006 .
^
Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A.
Visual Contrast Enhances Food and Liquid Intake in Advanced Alzheimer's Disease.
Clinical Nutrition (Edinburgh, Scotland) . 2004;23(4):533–538.
doi : 10.1016/j.clnu.2003.09.015 .
PMID 15297089 .
^
Dudek, Susan G. (2007).
Nutrition Essentials for Nursing Practice . Hagerstown, Maryland: Lippincott Williams & Wilkins. p. 360.
ISBN   0-7817-6651-6 . Retrieved
19 August
2008 .
^
Dennehy C.
Analysis of Patients' Rights: Dementia and PEG Insertion.
British Journal of Nursing . 2006;15(1):18–20.
doi : 10.12968/bjon.2006.15.1.20303 .
PMID 16415742 .
^
Chernoff R.
Tube Feeding Patients with Dementia.
Nutrition in Clinical Practice . 2006;21(2):142–6.
doi : 10.1177/0115426506021002142 .
PMID 16556924 .
^
Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R.
Predictors of Mortality in Patients with Alzheimer's Disease Living in Nursing Homes .
Journal of Neurology, Neurosurgery, and Psychiatry . 1999;67(1):59–65.
doi : 10.1136/jnnp.67.1.59 .
PMID 10369823 .
^
Medical issues:
Head B.
Palliative Care for Persons with Dementia.
Home Healthcare Nurse . 2003;21(1):53–60; quiz 61.
doi : 10.1097/00004045-200301000-00012 .
PMID 12544465 .
Friedlander AH, Norman DC, Mahler ME, Norman KM, Yagiela JA.
Alzheimer's Disease: Psychopathology, Medical Management and Dental Implications.
Journal of the American Dental Association . 2006;137(9):1240–51.
PMID 16946428 .
Belmin J.
Practical Guidelines for the Diagnosis and Management of Weight Loss in Alzheimer's Disease: A Consensus from Appropriateness Ratings of a Large Expert Panel.
The Journal of Nutrition, Health & Aging . 2007;11(1):33–7.
PMID 17315078 .
McCurry SM, Gibbons LE, Logsdon RG, Vitiello M, Teri L.
Training Caregivers to Change the Sleep Hygiene Practices of Patients with Dementia: The NITE-AD Project.
Journal of the American Geriatrics Society . 2003;51(10):1455–60.
doi : 10.1046/j.1532-5415.2003.51466.x .
PMID 14511168 .
Perls TT, Herget M.
Higher Respiratory Infection Rates on an Alzheimer's Special Care Unit and successful intervention.
Journal of the American Geriatrics Society . 1995;43(12):1341–4.
doi : 10.1111/j.1532-5415.1995.tb06611.x .
PMID 7490383 .
^
Shega JW, Levin A, Hougham GW, et al.
Palliative Excellence in Alzheimer Care Efforts (PEACE): A Program Description.
Journal of Palliative Medicine . 2003;6(2):315–20.
doi : 10.1089/109662103764978641 .
PMID 12854952 .
^
Sampson EL, Candy B, Jones L (2009).
"Enteral tube feeding for older people with advanced dementia (Intervention Review)" .
The Cochrane Database of Systematic Reviews
(2): CD007209.
doi : 10.1002/14651858.CD007209.pub2 .
PMID   19370678 .
^
a
b
c
d
Mölsä PK, Marttila RJ, Rinne UK.
Survival and Cause of Death in Alzheimer's Disease and Multi-Infarct Dementia.
Acta Neurologica Scandinavica . 1986;74(2):103–7.
doi : 10.1111/j.1600-0404.1986.tb04634.x .
PMID 3776457 .
^
a
b
Bowen JD, Malter AD, Sheppard L, et al.
Predictors of Mortality in Patients Diagnosed with Probable Alzheimer's Disease.
Neurology . 1996;47(2):433–9.
doi : 10.1212/wnl.47.2.433 .
PMID 8757016 .
^
a
b
Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M.
Functional Transitions and Active Life Expectancy Associated with Alzheimer Disease.
Archives of Neurology . 2003;60(2):253–9.
doi : 10.1001/archneur.60.2.253 .
PMID 12580712 .
^
a
b
Mölsä PK, Marttila RJ, Rinne UK.
Long-Term Survival and Predictors of Mortality in Alzheimer's Disease and Multi-Infarct Dementia.
Acta Neurologica Scandinavica . 1995;91(3):159–64.
doi : 10.1111/j.1600-0404.1995.tb00426.x .
PMID 7793228 .
^
Larson EB, Shadlen MF, Wang L, et al.
Survival after Initial Diagnosis of Alzheimer Disease.
Annals of Internal Medicine . 2004;140(7):501–9.
doi : 10.7326/0003-4819-140-7-200404060-00008 .
PMID 15068977 .
^
Jagger C, Clarke M, Stone A.
Predictors of Survival with Alzheimer's Disease: A Community-based Study.
Psychological Medicine . 1995;25(1):171–7.
doi : 10.1017/S0033291700028191 .
PMID 7792352 .
^
a
b
Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST.
Alzheimer Disease and Mortality: A 15-year Epidemiological Study.
Archives of Neurology . 2005;62(5):779–84.
doi : 10.1001/archneur.62.5.779 .
PMID 15883266 .
^
a
b
c
Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC.
Incidence and subtypes of dementia in three elderly populations of central Spain.
Journal of the Neurological Sciences . 2008;264(1–2):63–72.
doi : 10.1016/j.jns.2007.07.021 .
PMID 17727890 .
^
a
b
c
Di Carlo A, Baldereschi M, Amaducci L, et al.
Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study.
Journal of the American Geriatrics Society . 2002;50(1):41–8.
doi : 10.1046/j.1532-5415.2002.50006.x .
PMID 12028245 .
^
Andersen K, Launer LJ, Dewey ME, et al.
Gender Differences in the Incidence of AD and Vascular Dementia: The EURODEM Studies. EURODEM Incidence Research Group.
Neurology . 1999;53(9):1992–7.
doi : 10.1212/wnl.53.9.1992 .
PMID 10599770 .
^
Tejada-Vera B. (2013).
Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010.
Hyattsville, MD:
U.S. Department of Health and Human Services ,
Centers for Disease Control and Prevention ,
National Center for Health Statistics .
^
2000 U.S. estimates:
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA.
Alzheimer Disease in the US population: Prevalence Estimates Using the 2000 census.
Archives of Neurology . 2003;60(8):1119–22.
doi : 10.1001/archneur.60.8.1119 .
PMID 12925369 .
"Profiles of General Demographic Characteristics, 2000 Census of Population and Housing, United States"
(PDF) . U.S. Census Bureau. 2001.
Archived
(PDF)
from the original on 19 August 2008 . Retrieved
27 August
2008 .
^
a
b
Ferri CP, Prince M, Brayne C, Brodaty H, et al.
Global Prevalence of Dementia: A Delphi Consensus Study .
Lancet . 2005;366(9503):2112–7.
doi : 10.1016/S0140-6736(05)67889-0 .
PMID 16360788 .
^
World Health Organization (2006).
Neurological Disorders: Public Health Challenges . Switzerland: World Health Organization. pp. 204–207.
ISBN   978-92-4-156336-9 .
^
2006 prevalence estimate:
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM.
Forecasting the global burden of Alzheimer's disease .
Alzheimer's & Dementia . 2007 [Retrieved 18 June 2008];3(3):186–91.
doi : 10.1016/j.jalz.2007.04.381 .
PMID 19595937 .
World population prospects: the 2006 revision, highlights
[PDF]. 2007 [Retrieved 27 August 2008].
^
Auguste D.:
Alzheimer Alois.
Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex].
Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin . 1907;64(1–2):146–148.
(German) .
Alzheimer Alois.
About a Peculiar Disease of the Cerebral Cortex.
Alzheimer Disease and Associated Disorders . 1987;1(1):3–8.
PMID 3331112 .
Maurer Ulrike, Maurer Konrad (2003).
Alzheimer: The Life of a Physician and the Career of a Disease . New York: Columbia University Press. p. 270.
ISBN   0-231-11896-1 .
^
Berrios G E.
Alzheimer's Disease: A Conceptual History.
Int. J. Ger. Psychiatry . 1990;5(6):355–365.
doi : 10.1002/gps.930050603 .
^
Kraepelin Emil, Diefendorf A. Ross (translated by) (17 January 2007).
Clinical Psychiatry: A Textbook For Students And Physicians (Reprint) . Kessinger Publishing. p. 568.
ISBN   1-4325-0833-4 .
^
Katzman Robert, Terry Robert D, Bick Katherine L (editors) (1978).
Alzheimer's Disease: Senile Dementia and Related Disorders . New York: Raven Press. p. 595.
ISBN   0-89004-225-X .
^
Boller F, Forbes MM.
History of Dementia and Dementia in History: An Overview.
Journal of the Neurological Sciences . 1998;158(2):125–33.
doi : 10.1016/S0022-510X(98)00128-2 .
PMID 9702682 .
^
Amaducci LA, Rocca WA, Schoenberg BS.
Origin of the Distinction between Alzheimer's Disease and Senile Dementia: How History Can Clarify Nosology.
Neurology . 1986;36(11):1497–9.
doi : 10.1212/wnl.36.11.1497 .
PMID 3531918 .
^
Allegri RF, Butman J, Arizaga RL, et al.
Economic Impact of Dementia in Developing Countries: An Evaluation of Costs of Alzheimer-type Dementia in Argentina.
International Psychogeriatrics . 2007;19(4):705–18.
doi : 10.1017/S1041610206003784 .
PMID 16870037 .
^
Suh GH, Knapp M, Kang CJ.
The Economic Costs of Dementia in Korea, 2002.
International Journal of Geriatric Psychiatry . 2006;21(8):722–8.
doi : 10.1002/gps.1552 .
PMID 16858741 .
^
Wimo A, Jonsson L, Winblad B.
An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003.
Dementia and Geriatric Cognitive Disorders . 2006;21(3):175–81.
doi : 10.1159/000090733 .
PMID 16401889 .
^
a
b
c
Moore MJ, Zhu CW, Clipp EC.
Informal Costs of Dementia Care: Estimates from the National Longitudinal Caregiver Study.
The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences . 2001;56(4):S219–28.
doi : 10.1093/geronb/56.4.S219 .
PMID 11445614 .
^
Jönsson L, Eriksdotter Jönhagen M, Kilander L, et al.
Determinants of Costs of Care for Patients with Alzheimer's Disease.
International Journal of Geriatric Psychiatry . 2006;21(5):449–59.
doi : 10.1002/gps.1489 .
PMID 16676288 .
^
a
b
"The MetLife study of Alzheimer's disease: The caregiving experience"
(PDF) . MetLife Mature Market Institute. August 2006.
Archived
(PDF)
from the original on 8 January 2011 . Retrieved
5 February
2011 .
^
Schneider J, Murray J, Banerjee S, Mann A.
EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I—Factors associated with carer burden.
International Journal of Geriatric Psychiatry . 1999;14(8):651–661.
doi : 10.1002/(SICI)1099-1166(199908)14:8<651::AID-GPS992>3.0.CO;2-B .
PMID 10489656 .
^
Murray J, Schneider J, Banerjee S, Mann A.
EUROCARE: A Cross-National Study of Co-resident Spouse Carers for People with Alzheimer's Disease: II—A Qualitative Analysis of the Experience of Caregiving.
International Journal of Geriatric Psychiatry . 1999;14(8):662–7.
doi : 10.1002/(SICI)1099-1166(199908)14:8<662::AID-GPS993>3.0.CO;2-4 .
PMID 10489657 .
^
a
b
Zhu CW, Sano M.
Economic Considerations in the Management of Alzheimer's Disease .
Clinical Interventions in Aging . 2006;1(2):143–54.
doi : 10.2147/ciia.2006.1.2.143 .
PMID 18044111 .
^
Gaugler JE, Kane RL, Kane RA, Newcomer R.
Early Community-based Service Utilization and Its Effects on Institutionalization in Dementia Caregiving.
The Gerontologist . 2005;45(2):177–85.
doi : 10.1093/geront/45.2.177 .
PMID 15799982 .
^
Ritchie K, Lovestone S.
The Dementias.
Lancet . 2002;360(9347):1759–66.
doi : 10.1016/S0140-6736(02)11667-9 .
PMID 12480441 .
^
Brodaty H, Hadzi-Pavlovic D.
Psychosocial Effects on Carers of Living with Persons with Dementia.
The Australian and New Zealand Journal of Psychiatry . 1990;24(3):351–61.
doi : 10.3109/00048679009077702 .
PMID 2241719 .
^
Donaldson C, Tarrier N, Burns A.
Determinants of Carer Stress in Alzheimer's Disease.
International Journal of Geriatric Psychiatry . 1998;13(4):248–56.
doi : 10.1002/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0 .
PMID 9646153 .
^
Pusey H, Richards D.
A Systematic Review of the Effectiveness of Psychosocial Interventions for Carers of People with Dementia.
Aging & Mental Health . 2001;5(2):107–19.
doi : 10.1080/13607860120038302 .
PMID 11511058 .
^
Garrard P, Maloney LM, Hodges JR, Patterson K.
The Effects of Very Early Alzheimer's Disease on the Characteristics of Writing by a Renowned Author .
Brain . 2005;128(Pt 2):250–60.
doi : 10.1093/brain/awh341 .
PMID 15574466 .
^
Sherman FT.
Did President Reagan Have Mild cognitive Impairment While in Office? Living Longer with Alzheimer's Disease .
Geriatrics . 2004;59(9):11, 15.
PMID 15461232 .
^
Venneri A, Forbes-Mckay KE, Shanks MF.
Impoverishment of Spontaneous Language and the Prediction of Alzheimer's Disease.
Brain . 2005;128(Pt 4):E27.
doi : 10.1093/brain/awh419 .
PMID 15788549 .
^
"Hungary Legend Puskas Dies at 79" . BBC News. 17 November 2006 . Retrieved
25 January
2008 .
^
"Prime Ministers in History: Harold Wilson" . London: 10 Downing Street.
Archived
from the original on 25 August 2008 . Retrieved
18 August
2008 .
^
"Mi padre no reconoció al Rey pero notó el cariño" . Madrid: El País. 2008 . Retrieved
1 October
2008 .
^
"George Fernandes Being treated for Alzheimer's by Yoga Guru Ramdev" .
DNA . 19 January 2010.
Archived
from the original on 22 January 2010 . Retrieved
19 January
2010 .
^
"Chicago Rita Hayworth Gala" . Alzheimer's Association. 2007 . Retrieved
3 February
2010 .
^
"Charlton Heston has Alzheimer's Symptoms" . CNN. 9 August 2002.
Archived
from the original on 1 February 2008 . Retrieved
25 January
2008 .
^
"Harnett T. Kane, 73, Author of Books About the South" .
The New York Times . 14 September 1984 . Retrieved
2 August
2014 .
^
"Nobel Winner Kao Coping with Fame and Alzheimer's" . China Daily. 9 October 2009.
Archived
from the original on 24 January 2011 . Retrieved
6 February
2011 .
^
Pauli Michelle (12 December 2007).
"Pratchett Announces He Has Alzheimer's" . London: Guardian News and Media.
Archived
from the original on 29 September 2008 . Retrieved
18 August
2008 .
^
McFadden, Robert D. (January 18, 2011).
"R. Sargent Shriver, Peace Corps Leader, Dies at 95" .
The New York Times . Retrieved
2015-08-18 .
^
Bayley John (2000).
Iris: A Memoir of Iris Murdoch . London: Abacus.
ISBN   978-0-349-11215-2 .
OCLC   41960006 .
^
Sparks Nicholas (1996).
The notebook . Thorndike, Maine: Thorndike Press. p. 268.
ISBN   0-7862-0821-X .
^
"Thanmathra" . Webindia123.com . Retrieved
24 January
2008 .
^
Ogiwara Hiroshi (2004).
Ashita no Kioku
(in Japanese). Tōkyō: Kōbunsha.
ISBN   978-4-334-92446-1 .
OCLC   57352130 .
^
Munro Alice (2001).
Hateship, Friendship, Courtship, Loveship, Marriage: Stories . New York: A.A. Knopf.
ISBN   978-0-375-41300-1 .
OCLC   46929223 .
^
Malcolm and Barbara:
"Malcolm and Barbara: A love story" . Dfgdocs . Retrieved
24 January
2008 .
"Malcolm and Barbara: A love story" . BBC Cambridgeshire . Retrieved
2 March
2008 .
Plunkett J (7 August 2007).
"Alzheimer's film-maker to face ITV lawyers" . London: Guardian Media.
Archived
from the original on 15 January 2008 . Retrieved
24 January
2008 .
^
"Clinical Trials. Found 1504 studies with search of: alzheimer" . US National Institutes of Health . Retrieved
30 October
2014 .
^
Lashuel HA, Hartley DM, Balakhaneh D, et al.
New Class of Inhibitors of Beta-amyloid Fibril Formation. Implications for the Mechanism of Pathogenesis in Alzheimer's Disease .
The Journal of Biological Chemistry . 2002;277(45):42881–42890.
doi : 10.1074/jbc.M206593200 .
PMID 12167652 .
^
Dodel R, Neff F, Noelker C, et al.
Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease: Rationale and Current Evidence .
Drugs . 2010;70(5):513–528.
doi : 10.2165/11533070-000000000-00000 .
PMID 20329802 .
^
Vaccination:
Hawkes CA, McLaurin J.
Immunotherapy as Treatment for Alzheimer's Disease.
Expert Review of Neurotherapeutics . 2007;7(11):1535–48.
doi : 10.1586/14737175.7.11.1535 .
PMID 17997702 .
Solomon B.
Clinical Immunologic Approaches for the Treatment of Alzheimer's Disease.
Expert Opinion on Investigational Drugs . 2007;16(6):819–28.
doi : 10.1517/13543784.16.6.819 .
PMID 17501694 .
Woodhouse A, Dickson TC, Vickers JC.
Vaccination Strategies for Alzheimer's Disease: A New Hope?.
Drugs & Aging . 2007;24(2):107–19.
doi : 10.2165/00002512-200724020-00003 .
PMID 17313199 .
^
"Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects" .
Clinical Trial . US National Institutes of Health. 11 March 2008 . Retrieved
5 June
2008 .
^
"Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects with Alzheimer's Disease" . US National Institutes of Health . Retrieved
5 June
2008 .
^
"Alzheimer's Disease Vaccine Trial Suspended on Safety Concern" . Medpage Today. 18 April 2008 . Retrieved
14 June
2008 .
^
"Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease/ Apo_e4 Non-carriers"
(Clinical Trial). US National Institutes of Health. 29 February 2008.
Archived
from the original on 22 March 2008 . Retrieved
23 March
2008 .
^
"Safety, Tolerability and Efficacy Study to Evaluate Subjects with Mild Cognitive Impairment"
(Clinical Trial). US National Institutes of Health. 11 March 2008 . Retrieved
23 March
2008 .
^
"Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients with Early Alzheimer's Disease"
(Clinical Trial). US National Institutes of Health. 13 January 2008 . Retrieved
23 March
2008 .
^
Etanercept research:
Tobinick E.
Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.
CNS Drugs . September 2009;23(9):713–25.
doi : 10.2165/11310810-000000000-00000 .
PMID 19689163 .
Tobinick E, Gross H, Weinberger A, Cohen H.
TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study .
Medscape General Medicine . 2006;8(2):25.
PMID 16926764 .
Griffin WS.
Perispinal etanercept: Potential as an Alzheimer Therapeutic .
Journal of Neuroinflammation . 2008;5:3.
doi : 10.1186/1742-2094-5-3 .
PMID 18186919 .
Tobinick E.
Perispinal Etanercept for Treatment of Alzheimer's Disease.
Current Alzheimer Research . 2007;4(5):550–2.
doi : 10.2174/156720507783018217 .
PMID 18220520 .
Cheng X, Shen Y, Li R.
Targeting TNF: a therapeutic strategy for Alzheimer's disease.
Drug Discovery Today . 4 July 2014.
doi : 10.1016/j.drudis.2014.06.029 .
PMID 24998784 .
^
Wischik Claude M, Bentham Peter, Wischik Damon J, Seng Kwang Meng.
Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks .
Alzheimer's & Dementia . 2008 [Retrieved 30 July 2008];4(4):T167.
doi : 10.1016/j.jalz.2008.05.438 .
^
Harrington C, Rickard J, Horsley D, et al.
Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease.
Alzheimer's & Dementia . 2008;4(4):T120–T121.
doi : 10.1016/j.jalz.2008.05.259 .
^
Doody RS, Gavrilova SI, Sano M, et al.
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Lancet . 2008;372(9634):207–15.
doi : 10.1016/S0140-6736(08)61074-0 .
PMID 18640457 .
^
Bezprozvanny I.
The rise and fall of Dimebon.
Drug News & Perspectives . October 2010;23(8):518–23.
doi : 10.1358/dnp.2010.23.8.1500435 .
PMID 21031168 .
^
"Pfizer And Medivation announce results from two phase 3 studies in Dimebon (latrepirdine*) Alzheimer's disease clinical development program (NASDAQ:MDVN)"
(Press release) . Retrieved
16 November
2012 .
^
Wendler A, Wehling M.
Translatability scoring in drug development: eight case studies.
Journal of Translational Medicine . 2012;10(10):39.
doi : 10.1186/1479-5876-10-39 .
PMID 22397594 .
^
Baddeley TC, McCaffrey J, Storey JM, et al. (15 October 2014). "Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease".
J Pharmacol Exp Ther
352
(1): 110–118.
doi : 10.1124/jpet.114.219352 .
PMID   25320049 .
^
Wischik CM, Harrington CR, Storey JM.
Tau-aggregation inhibitor therapy for Alzheimer's disease.
Biochem Pharmacol . 15 April 2014;88(4):529–39.
doi : 10.1016/j.bcp.2013.12.008 .
PMID 24361915 .
^
a
b
Martin C, Solís L, Concha MI, Otth C.
Herpes simplex virus tipo 1 como factor de riesgo asociado con la enfermedad de Alzheimer [Herpes Simplex Virus Type 1 as Risk Factor Associated to Alzheimer Disease].
Revista Médica De Chile . June 2011;139(6):779–86. Spanish.
doi : 10.4067/S0034-98872011000600013 .
PMID 22051760 .
^
Wozniak MA, Mee AP, Itzhaki RF.
Herpes Simplex Virus type 1 DNA Is Located within Alzheimer's Disease Amyloid Plaques.
The Journal of Pathology . 2008;217(1):131–138.
doi : 10.1002/path.2449 .
PMID 18973185 .
^
Marciniak R, Sheardova K, Čermáková P, Hudeček D, Šumec R, Hort J.
Effect of Meditation on Cognitive Functions in Context of Aging and Neurodegenerative Diseases .
Frontiers in Behavioral Neuroscience . 2014;8:17.
doi : 10.3389/fnbeh.2014.00017 .
PMID 24478663 .
^
Clark CM, Schneider JA, Bedell BJ, et al.
FDA Recommends Approval of New Compound in Alzheimer's Detection.
JAMA . 19 January 2011;305(3):275–83.
doi : 10.1001/jama.2010.2008 .
PMID 21245183 .
^
Larouche E, Hudon C, Goulet S (January 2015). "Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: An interdisciplinary perspective".
Behav Brain Res
1
(276): 199–212.
doi : 10.1016/j.bbr.2014.05.058 .
^
"Autopsies reveal signs of Alzheimer’s in growth-hormone patients" .
^
"Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy" .
^
Dougall NJ, Bruggink S, Ebmeier KP.
Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia.
The American Journal of Geriatric Psychiatry . 2004;12(6):554–70.
doi : 10.1176/appi.ajgp.12.6.554 .
PMID 15545324 .
^
Carpenter AP, Pontecorvo MJ, Hefti FF, Skovronsky DM.
The Use of the Exploratory IND in the Evaluation and Development of 18 F-PET Radiopharmaceuticals for Amyloid Imaging in the Brain: A Review of One Company's Experience.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging . August 2009;53(4):387–93.
PMID 19834448 .
^
Leung K (8 April 2010).
"(E)-4-(2-(6-(2-(2-(2-( 18 F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine [[ 18 F]AV-45] ]]" .
Molecular Imaging and Contrast Agent Database . Retrieved
24 June
2010 .
^
Rabinovici GD, Jagust WJ.
Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypotheses in Vivo .
Behavioural Neurology . 2009;21(1):117–28.
doi : 10.3233/BEN-2009-0232 .
PMID 19847050 .
PMC
2804478 .
^
O'Brien JT.
Role of Imaging Techniques in the Diagnosis of Dementia.
The British Journal of Radiology . December 2007;80(Spec No 2):S71–7.
doi : 10.1259/bjr/33117326 .
PMID 18445747 .
Further reading
Listen to this article
( info/dl )
Sorry, your browser either has JavaScript disabled or does not have any supported player.
You can
download the clip
or
download a player
to play the clip in your browser.
This audio file was created from a revision of the " Alzheimer's disease " article dated 2008-09-12, and does not reflect subsequent edits to the article. ( Audio help )
More spoken articles
Library resources
about
Alzheimer's Disease
Resources in your library
Resources in other libraries
Alzheimer's Disease: Unraveling the Mystery . US Department of Health and Human Services, National Institute on Aging, NIH. 2008.
Can Alzheimer's Disease Be Prevented?
(PDF) . US Department of Health and Human Services, National Institute on Aging, NIH. 2009.
Caring for a Person with Alzheimer's Disease: Your Easy-to-Use Guide from the National Institute on Aging . US Department of Health and Human Services, National Institute on Aging, NIH. 2009.
Russell D, Barston S, White M (19 December 2007).
"Alzheimer's Behavior Management: Learn to Manage Common Behavior Problems" . helpguide.org.
Archived
from the original on 23 February 2008 . Retrieved
29 February
2008 .
Irvine K,
Laws KR , Gale TM, Kondel TK.
Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis.
Journal of Clinical and Experimental Neuropsychology . 2012;34(9):989–98.
doi : 10.1080/13803395.2012.712676 .
PMID 22913619 .
External links
Wikimedia Commons has media related to
Alzheimer's disease .
Alzheimer's disease
at
DMOZ
v
t
e
Mental
and
behavioral disorders
( F
290–319 )
Neurological/symptomatic
Dementia
Mild cognitive impairment
Alzheimer's disease
Vascular dementia
Pick's disease
Creutzfeldt–Jakob disease
Huntington's disease
Parkinson's disease
AIDS dementia complex
Frontotemporal dementia
Sundowning
Wandering
Autism spectrum
Autism
Asperger syndrome
Savant syndrome
PDD-NOS
High-functioning autism
Other
Delirium
Post-concussion syndrome
Organic brain syndrome
Psychoactive
substances,
substance abuse ,
drug abuse
and substance-related disorders
Intoxication / Drug overdose
Physical dependence
Substance dependence
Rebound effect
Double rebound
Withdrawal
Schizophrenia ,
schizotypal
and
delusional
Psychosis
Schizoaffective disorder
Schizophreniform disorder
Brief reactive psychosis
Schizophrenia
Disorganized schizophrenia
Delusional disorder
Folie à deux
Mood
(affective)
Mania
Bipolar disorder
( Bipolar I
Bipolar II
Cyclothymia
Bipolar NOS )
Depression
( Major depressive disorder
Dysthymia
Seasonal affective disorder
Atypical depression
Melancholic depression )
Neurotic ,
stress -related and
somatoform
Anxiety disorder
Phobia
Agoraphobia
Social anxiety
Social phobia
( Anthropophobia )
Specific phobia
( Claustrophobia )
Specific social phobia
Other
Panic disorder
Panic attack
Generalized anxiety disorder
OCD
stress
( Acute stress reaction
PTSD )
Adjustment disorder
Adjustment disorder with depressed mood
Somatoform disorder
Somatization disorder
Body dysmorphic disorder
Hypochondriasis
Nosophobia
Da Costa's syndrome
Psychalgia
Conversion disorder
( Ganser syndrome
Globus pharyngis )
Neurasthenia
Mass psychogenic illness
Dissociative disorder
Dissociative identity disorder
Psychogenic amnesia
Fugue state
Depersonalization disorder
Physiological/physical behavioral
Eating disorder
Anorexia nervosa
Bulimia nervosa
Rumination syndrome
NOS
Nonorganic
sleep disorders
( Nonorganic hypersomnia
Nonorganic insomnia )
Parasomnia
( REM sleep behavior disorder
Night terror
Nightmare )
Sexual
dysfunction
sexual desire
( Hypoactive sexual desire disorder
Hypersexuality )
sexual arousal
( Female sexual arousal disorder )
Erectile dysfunction
orgasm
( Anorgasmia
Delayed ejaculation
Premature ejaculation
Sexual anhedonia )
pain
( Vaginismus
Dyspareunia )
Postnatal
Postpartum depression
Postnatal psychosis
Adult personality and behavior
Gender dysphoria
Sexual maturation disorder
Ego-dystonic sexual orientation
Sexual relationship disorder
Paraphilia
( Voyeurism
Fetishism )
Other
Personality disorder
Impulse control disorder
( Kleptomania
Trichotillomania
Pyromania
Dermatillomania )
Body-focused repetitive behavior
Factitious disorder
( Münchausen syndrome )
Disorders typically diagnosed in childhood
Intellectual disability
X-linked intellectual disability
( Lujan-Fryns syndrome )
Psychological development
( developmental disabilities )
Specific
Pervasive
Autism spectrum disorders
Emotional and behavioral
ADHD
Conduct disorder
( ODD )
Emotional/behavioral disorder
( Separation anxiety disorder )
social functioning
( Selective mutism
RAD
DAD )
Tic disorder
( Tourette syndrome )
Speech
( Stuttering
Cluttering )
Movement disorder
( Stereotypic )
Symptoms and uncategorized
Catatonia
False pregnancy
Intermittent explosive disorder
Psychomotor agitation
Stereotypy
Psychogenic non-epileptic seizures
Klüver-Bucy syndrome
v
t
e
Index of
psychology
and
psychiatry
Description
Mental processes
Disorders
Mental and behavioral
ADHD
OCD
Tourette's
Mood
Developmental
pervasive
dyslexia and specific
Substance-related
alcohol
Emotional and behavioral disorders
Symptoms and signs
Evaluation and testing
Treatment
Psychotherapy
CBT
Drugs
depression
antipsychotics
anxiety
dementia
hypnotics and sedatives
v
t
e
Pathology
of the
nervous system , primarily
CNS
( G04–G47 ,
323–349 )
Inflammation
Brain
Encephalitis
Viral encephalitis
Herpesviral encephalitis
Limbic encephalitis
Encephalitis lethargica
Cavernous sinus thrombosis
Brain abscess
Amoebic
Spinal cord
Myelitis :
Poliomyelitis
Demyelinating disease
Transverse myelitis
Tropical spastic paraparesis
Epidural abscess
Both/either
Encephalomyelitis
Acute disseminated
Myalgic
Meningoencephalitis
Brain /
encephalopathy
Degenerative
Extrapyramidal
and
movement disorders
Basal ganglia disease
Parkinsonism
PD
Postencephalitic
NMS
PKAN
Tauopathy
PSP
Striatonigral degeneration
Hemiballismus
HD
OA
Dyskinesia
Dystonia
Status dystonicus
Spasmodic torticollis
Meige's
Blepharospasm
Athetosis
Chorea
Choreoathetosis
Myoclonus
Myoclonic epilepsy
Akathisia
Tremor
Essential tremor
Intention tremor
Restless legs
Stiff person
Dementia
Tauopathy
Alzheimer's
Early-onset
Primary progressive aphasia
Frontotemporal dementia / Frontotemporal lobar degeneration
Pick's
Dementia with Lewy bodies
Posterior cortical atrophy
Vascular dementia
Mitochondrial disease
Leigh's disease
Demyelinating
autoimmune
Multiple sclerosis
Neuromyelitis optica
Schilder's disease
hereditary
Adrenoleukodystrophy
Alexander
Canavan
Krabbe
ML
PMD
VWM
MFC
CAMFAK syndrome
Central pontine myelinolysis
Marchiafava-Bignami disease
Alpers' disease
Episodic/
paroxysmal
Seizure / epilepsy
Focal
Generalised
Status epilepticus
Myoclonic epilepsy
Headache
Migraine
Familial hemiplegic
Cluster
Tension
Cerebrovascular
TIA
Amaurosis fugax
Transient global amnesia
Acute aphasia
Stroke
MCA
ACA
PCA
Foville's
Millard-Gubler
Lateral medullary
Weber's
Lacunar stroke
Sleep disorders
Insomnia
Hypersomnia
Sleep apnea
Obstructive
Ondine's curse
Narcolepsy
Cataplexy
Kleine-Levin
Circadian rhythm sleep disorder
Advanced sleep phase disorder
Delayed sleep phase disorder
Non-24-hour sleep–wake disorder
Jet lag
CSF
Intracranial hypertension
Hydrocephalus / NPH
Choroid plexus papilloma
Idiopathic intracranial hypertension
Cerebral edema
Intracranial hypotension
Other
Brain herniation
Reye's
Hepatic encephalopathy
Toxic encephalopathy
Hashimoto's encephalopathy
Spinal cord /
myelopathy
Syringomyelia
Syringobulbia
Morvan's syndrome
Vascular myelopathy
Foix-Alajouanine syndrome
Spinal cord compression
Both/either
Degenerative
SA
Friedreich's ataxia
Ataxia telangiectasia
MND
UMN
only:
Primary lateral sclerosis
Pseudobulbar palsy
Hereditary spastic paraplegia
LMN
only:
Distal hereditary motor neuropathies
Spinal muscular atrophies
SMA
SMAX1
SMAX2
DSMA1
Congenital DSMA
SMA-PCH
SMA-LED
SMA-PME
Progressive muscular atrophy
Progressive bulbar palsy
Fazio–Londe
Infantile progressive bulbar palsy
both:
Amyotrophic lateral sclerosis
v
t
e
Index of the
central nervous system
Description
Anatomy
meninges
cortex
association fibers
commissural fibers
lateral ventricles
basal ganglia
diencephalon
mesencephalon
pons
cerebellum
medulla
spinal cord
tracts
Physiology
neutrotransmission
enzymes
intermediates
Development
Disease
Addiction
Cerebral palsy
Meningitis
Demyelinating diseases
Seizures and epilepsy
Headache
Stroke
Sleep
Congenital
Injury
Neoplasms and cancer
Other
paralytic syndromes
ALS
Symptoms and signs
head and neck
eponymous
lesions
Tests
CSF
Treatment
Procedures
Drugs
general anesthetics
analgesics
dependence
epilepsy
cholinergics
migraine
Parkinson's
vertigo
other
v
t
e
Metabolic disease :
amyloidosis
( E85 ,
277.3 )
Common
amyloid
forming proteins
AA
ATTR
Aβ2M
AL
Aβ / APP
AIAPP
ACal
APro
AANF
ACys
ABri
Systemic amyloidosis
AL amyloidosis
AA amyloidosis
Aβ2M/Haemodialysis-associated
AGel/Finnish type
AA/Familial Mediterranean fever
ATTR/Transthyretin-related hereditary
Organ-limited amyloidosis
Heart
AANF/Isolated atrial
Brain
Familial amyloid neuropathy
ACys+ABri/Cerebral amyloid angiopathy
Aβ/Alzheimer's disease
Kidney
AApoA1+AFib+ALys/Familial renal
Cutaneous
Primary cutaneous amyloidosis
Amyloid purpura
Endocrine
Thyroid
ACal/Medullary thyroid cancer
Pituitary
APro/Prolactinoma
Pancreas
AIAPP/Insulinoma
AIAPP/Diabetes mellitus type 2
برگرفته از « https://fa.wikipedia.org/w/index.php?title=بیماری_آلزایمر&oldid=16033135 »
رده‌ها :
بیماری آلزایمر اختلال‌های یادگیری بیماریهای مرتبط با هرپس سیمپلکس بیماری‌های اعصاب بیماری‌های با علت ناشناخته بیماری‌های مرتبط با پیری تشخیص روانپزشکی زبان‌پریشی‌ها زوال عقل مسئله‌های حل‌نشده در عصب‌شناسی رده‌های پنهان:
نیاز به بازبینی انسان مقاله‌های نیازمند به ویکی‌سازی مقاله‌های دارای واژگان به زبان انگلیسی انبار رده با پیوند محلی مشابه در ویکی‌داده
منوی ناوبری
ابزارهای شخصی
ورود ایجاد حساب کاربری
گویش‌ها
فضاهای نام
بحث
مقاله
جستجو
بیشتر
بازدیدها
نمایش تاریخچه
ویرایش
خواندن
بازدید محتوا
صفحهٔ اصلی رویدادهای کنونی مقالهٔ تصادفی اهدا
همکاری
تغییرات اخیر ویکی‌نویس شوید! راهنما تماس با ویکی‌پدیا
نسخه‌برداری
ایجاد کتاب دریافت به‌صورت PDF نسخهٔ قابل چاپ
ابزارها
پیوندها به این صفحه تغییرات مرتبط بارگذاری پرونده صفحه‌های ویژه پیوند پایدار اطلاعات صفحه آیتم ویکی‌داده یادکرد پیوند این مقاله
به زبان‌های دیگر
Afrikaans Alemannisch Aragonés العربية অসমীয়া Asturianu Azərbaycanca Žemaitėška Беларуская Беларуская (тарашкевіца)‎ Български বাংলা Bosanski Català کوردیی ناوەندی Čeština Cymraeg Dansk Deutsch Ελληνικά English Esperanto Español Eesti Euskara Suomi Français Frysk Gaeilge 贛語 Galego עברית हिन्दी Fiji Hindi Hrvatski Magyar Հայերեն Bahasa Indonesia Ilokano Ido Íslenska Italiano 日本語 Basa Jawa ქართული Қазақша ಕನ್ನಡ 한국어 Latina Lëtzebuergesch Lietuvių Latviešu Македонски മലയാളം Монгол Bahasa Melayu မြန်မာဘာသာ नेपाली Nederlands Norsk nynorsk Norsk bokmål Occitan ଓଡ଼ିଆ ਪੰਜਾਬੀ Polski پنجابی Português Română Русский Русиньскый Sicilianu Scots Srpskohrvatski / српскохрватски සිංහල Simple English Slovenčina Slovenščina Shqip Српски / srpski Basa Sunda Svenska Kiswahili தமிழ் తెలుగు ไทย Tagalog Türkçe Татарча/tatarça Українська اردو Tiếng Việt Winaray ייִדיש 中文 粵語
ویرایش پیوندها
این صفحه آخرین‌بار در ‏۳ اکتبر ۲۰۱۵ ساعت ‏۱۸:۳۶ تغییر یافته‌است.
همهٔ نوشته‌ها تحت
مجوز Creative Commons Attribution/Share-Alike
در دسترس است؛
برای جزئیات بیشتر
شرایط استفاده
را بخوانید.
ویکی‌پدیا® علامتی تجاری متعلق به سازمان غیرانتفاعی
بنیاد ویکی‌مدیا
است.
سیاست محرمانگی
دربارهٔ ویکی‌پدیا
تکذیب‌نامه‌ها
توسعه‌دهندگان
نمای تلفن همراه